<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Transplantation</journal-id><journal-id journal-id-type="iso-abbrev">Transplantation</journal-id><journal-id journal-id-type="publisher-id">TP</journal-id><journal-title-group><journal-title>Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0041-1337</issn><issn pub-type="epub">1534-6080</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25083614</article-id><article-id pub-id-type="pmc">4281164</article-id><article-id pub-id-type="publisher-id">TP131413</article-id><article-id pub-id-type="doi">10.1097/TP.0000000000000250</article-id><article-id pub-id-type="art-access-id">00034</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title>A Randomized 2×2 Factorial Trial, Part 1: Single-Dose Rabbit Antithymocyte Globulin Induction May Improve Renal Transplantation Outcomes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stevens</surname><given-names>R. Brian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Foster</surname><given-names>Kirk W.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Miles</surname><given-names>Clifford D.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>James T.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kalil</surname><given-names>Andre C.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Florescu</surname><given-names>Diana F.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sandoz</surname><given-names>John P.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rigley</surname><given-names>Theodore H.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Kathleen J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Skorupa</surname><given-names>Jill Y.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kellogg</surname><given-names>Anna M.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Malik</surname><given-names>Tamer</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wrenshall</surname><given-names>Lucile E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup> Department of Surgery, Wright State University Boonshoft School of Medicine, Dayton, OH.</aff><aff id="aff2"><sup>2</sup> Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.</aff><aff id="aff3"><sup>3</sup> Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.</aff><aff id="aff4"><sup>4</sup> Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK.</aff><aff id="aff5"><sup>5</sup> Sigma Analytics, Inc., Anthem, AZ.</aff><aff id="aff6"><sup>6</sup> Department of Surgery, Methodist Hospital, Houston, TX.</aff><author-notes><corresp>Correspondence: R. Brian Stevens, MD, PhD, FACS, Department of Surgery, Wright State University Boonshoft School of Medicine, One Wyoming Street, 7819 WCHE, Dayton, OH 45409. (<email>rbstevens1@icloud.com</email>)</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2014</year></pub-date><volume>99</volume><issue>1</issue><fpage>197</fpage><lpage>209</lpage><history><date date-type="received"><day>13</day><month>1</month><year>2014</year></date><date date-type="rev-request"><day>31</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Lippincott Williams &amp; Wilkins</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0">http://creativecommons.org/licenses/by-nc-nd/3.0</ext-link>.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="tp-99-197.pdf"></self-uri><abstract abstract-type="toc"><p><offsets xml_i="5653" xml_f="5707" txt_i="11" txt_f="65">Supplemental digital content is available in the text.</offsets></p></abstract><abstract><sec><title><offsets xml_i="5744" xml_f="5754" txt_i="77" txt_f="87">Background</offsets></title><p><offsets xml_i="5765" xml_f="5852" txt_i="88" txt_f="175">We conducted a randomized and unblinded 2×2 sequential-factorial trial, composed of an </offsets><italic><offsets xml_i="5860" xml_f="5873" txt_i="175" txt_f="188">induction arm</offsets></italic><offsets xml_i="5882" xml_f="5983" txt_i="188" txt_f="289"> (part 1) comparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a </offsets><italic><offsets xml_i="5991" xml_f="6006" txt_i="289" txt_f="304">maintenance arm</offsets></italic><offsets xml_i="6015" xml_f="6228" txt_i="304" txt_f="517"> (part 2) comparing tacrolimus minimization versus withdrawal. We report the long-term safety and efficacy of SD-rATG induction in the context of early steroid withdrawal and tacrolimus minimization or withdrawal.</offsets></p></sec><sec><title><offsets xml_i="6250" xml_f="6257" txt_i="519" txt_f="526">Methods</offsets></title><p><offsets xml_i="6268" xml_f="6909" txt_i="527" txt_f="1168">Patients (n=180) received 6 mg/kg rATG, SD or four alternate-day doses (1.5 mg/kg/dose), with early steroid withdrawal and tacrolimus or sirolimus maintenance. After 6 months targeted maintenance levels were tacrolimus, 2 to 4 ng/mL and sirolimus, 4 to 6 ng/mL or, if calcineurin inhibitor–withdrawn, sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day. Primary endpoints were renal function (abbreviated modification of diet in renal disease) and chronic graft histopathology (Banff). Secondary endpoints included patient survival, graft survival, biopsy-proven rejection, and infectious or noninfectious complications.</offsets></p></sec><sec><title><offsets xml_i="6931" xml_f="6938" txt_i="1170" txt_f="1177">Results</offsets></title><p><offsets xml_i="6949" xml_f="7144" txt_i="1178" txt_f="1373">Follow-up averaged longer than 4 years. Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between groups. The SD-rATG associated with improved renal function (2-36 months; </offsets><italic><offsets xml_i="7152" xml_f="7153" txt_i="1373" txt_f="1374">P</offsets></italic><offsets xml_i="7162" xml_f="7365" txt_i="1374" txt_f="1574">&lt;0.001) in deceased donor recipients. The SD-rATG associated with quicker lymphocyte, CD4 T cell, and CD4-CD8 recovery and fewer infections. Cox multivariate hazard modeling showed divided-dose–rATG (</offsets><italic><offsets xml_i="7373" xml_f="7374" txt_i="1574" txt_f="1575">P</offsets></italic><offsets xml_i="7383" xml_f="7408" txt_i="1575" txt_f="1600">=0.019), deceased donor (</offsets><italic><offsets xml_i="7416" xml_f="7417" txt_i="1600" txt_f="1601">P</offsets></italic><offsets xml_i="7426" xml_f="7454" txt_i="1601" txt_f="1629">=0.003), serious infection (</offsets><italic><offsets xml_i="7462" xml_f="7463" txt_i="1629" txt_f="1630">P</offsets></italic><offsets xml_i="7472" xml_f="7511" txt_i="1630" txt_f="1669">=0.0.018), and lower lymphocyte count (</offsets><italic><offsets xml_i="7519" xml_f="7520" txt_i="1669" txt_f="1670">P</offsets></italic><offsets xml_i="7529" xml_f="7656" txt_i="1670" txt_f="1797">=0.001) associated with increased mortality. Patients with all four covariates showed a 27-fold increased likelihood of death (</offsets><italic><offsets xml_i="7664" xml_f="7665" txt_i="1797" txt_f="1798">P</offsets></italic><offsets xml_i="7674" xml_f="7814" txt_i="1798" txt_f="1938">=0.00002). Chronic graft histopathology, rejection rates, and death-censored graft survival were not significantly different between groups.</offsets></p></sec><sec><title><offsets xml_i="7836" xml_f="7846" txt_i="1940" txt_f="1950">Conclusion</offsets></title><p><offsets xml_i="7857" xml_f="8109" txt_i="1951" txt_f="2203">The SD-rATG induction improves the 3-year renal function in recipients of deceased donor kidneys. This benefit, along with possibly improved patient survival and fewer infections suggest that how rATG is administered may impact its efficacy and safety.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="8370" xml_f="8452" txt_i="2212" txt_f="2294">Modern immunosuppressants reduce rejection with minimally improved graft survival.</offsets><sup><xref rid="R1" ref-type="bibr"><offsets xml_i="8488" xml_f="8489" txt_i="2294" txt_f="2295">1</offsets></xref></sup><offsets xml_i="8502" xml_f="8728" txt_i="2295" txt_f="2521"> Reduced calcineurin inhibitor (CNI) exposure associates with improved early renal graft function, but after prolonged CNI exposure, even complete withdrawal may not improve renal function because of irreversible renal injury,</offsets><sup><xref rid="R2" ref-type="bibr"><offsets xml_i="8764" xml_f="8765" txt_i="2521" txt_f="2522">2</offsets></xref></sup><offsets xml_i="8778" xml_f="8867" txt_i="2522" txt_f="2611"> and diminished CNI use may risk late or subclinical rejection, antibody-mediated injury,</offsets><sup><xref rid="R3" ref-type="bibr"><offsets xml_i="8903" xml_f="8904" txt_i="2611" txt_f="2612">3</offsets></xref><offsets xml_i="8911" xml_f="8912" txt_i="2612" txt_f="2613">-</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="8943" xml_f="8944" txt_i="2613" txt_f="2614">8</offsets></xref></sup><offsets xml_i="8957" xml_f="8972" txt_i="2614" txt_f="2629"> or graft loss.</offsets><sup><xref rid="R9" ref-type="bibr"><offsets xml_i="9008" xml_f="9009" txt_i="2629" txt_f="2630">9</offsets></xref><offsets xml_i="9016" xml_f="9017" txt_i="2630" txt_f="2631">-</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="9049" xml_f="9051" txt_i="2631" txt_f="2633">12</offsets></xref></sup><offsets xml_i="9064" xml_f="9379" txt_i="2633" txt_f="2948"> In addition, steroid-mediated metabolic derangements contribute to morbidity among patients with functioning grafts. In a large meta-analysis, cardiovascular risk-factor reduction was associated with steroid withdrawal, with a small increased risk of acute rejection that did not impact patient and graft survival.</offsets><sup><xref rid="R13" ref-type="bibr"><offsets xml_i="9416" xml_f="9418" txt_i="2948" txt_f="2950">13</offsets></xref><offsets xml_i="9425" xml_f="9426" txt_i="2950" txt_f="2951">-</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="9458" xml_f="9460" txt_i="2951" txt_f="2953">15</offsets></xref></sup></p><p><offsets xml_i="9480" xml_f="9672" txt_i="2954" txt_f="3146">Both CNI and steroid minimization or avoidance may be facilitated by maintenance immunosuppression that includes a mammalian target of rapamycin inhibitor (mTORi; e.g., sirolimus, everolimus).</offsets><sup><xref rid="R16" ref-type="bibr"><offsets xml_i="9709" xml_f="9711" txt_i="3146" txt_f="3148">16</offsets></xref></sup><offsets xml_i="9724" xml_f="9784" txt_i="3148" txt_f="3208"> However, these drugs present their own clinical challenges.</offsets><sup><xref rid="R17" ref-type="bibr"><offsets xml_i="9821" xml_f="9823" txt_i="3208" txt_f="3210">17</offsets></xref><offsets xml_i="9830" xml_f="9831" txt_i="3210" txt_f="3211">-</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="9863" xml_f="9865" txt_i="3211" txt_f="3213">20</offsets></xref></sup><offsets xml_i="9878" xml_f="10075" txt_i="3213" txt_f="3410"> Although early replacement of CNI with mTORi may improve renal function, patients with glomerular filtration rate (GFR) less than 40 mL per min respond with proteinuria and deteriorating function.</offsets><sup><xref rid="R21" ref-type="bibr"><offsets xml_i="10112" xml_f="10114" txt_i="3410" txt_f="3412">21</offsets></xref></sup><offsets xml_i="10127" xml_f="10308" txt_i="3412" txt_f="3593"> However, mTORi have advantages as well (e.g., antineoplastic properties), and the potent mTORi-CNI synergy can reduce the risk of rejection with minimized CNI and steroid exposure.</offsets><sup><xref rid="R16" ref-type="bibr"><offsets xml_i="10345" xml_f="10347" txt_i="3593" txt_f="3595">16</offsets></xref><offsets xml_i="10354" xml_f="10356" txt_i="3595" txt_f="3597">, </offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="10388" xml_f="10390" txt_i="3597" txt_f="3599">22</offsets></xref><offsets xml_i="10397" xml_f="10399" txt_i="3599" txt_f="3601">, </offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="10431" xml_f="10433" txt_i="3601" txt_f="3603">23</offsets></xref></sup><offsets xml_i="10446" xml_f="10640" txt_i="3603" txt_f="3797"> Adverse mTORi wound healing effects can be minimized by delayed introduction, an approach that minimizes sirolimus dose-dependent side effects (e.g., mouth ulcers, hyperlipidemia, proteinuria).</offsets><sup><xref rid="R18" ref-type="bibr"><offsets xml_i="10677" xml_f="10679" txt_i="3797" txt_f="3799">18</offsets></xref></sup></p><p><offsets xml_i="10699" xml_f="11160" txt_i="3800" txt_f="4261">Since 1999, our goal has been to prevent kidney rejection while avoiding immunosuppressant side effects through early steroid withdrawal (ESW) and reduced CNI and mTORi maintenance. Our long-term blood-level targets were: tacrolimus, 6-8 ng/mL and sirolimus, 8-12 ng/mL. Reducing the risk of early acute rejection with this ESW protocol depended on profound lymphocyte depletion with rabbit antithymocyte globulin (rATG), four 1.5 mg/kg doses on alternate days.</offsets><sup><xref rid="R24" ref-type="bibr"><offsets xml_i="11197" xml_f="11199" txt_i="4261" txt_f="4263">24</offsets></xref></sup><offsets xml_i="11212" xml_f="11426" txt_i="4263" txt_f="4477"> Although patient and graft survivals were not different, renal function did not improve compared to 8 to 12 ng/mL of tacrolimus and 1 g two times per day of mycophenolate mofetil (MMF), with or without prednisone.</offsets><sup><xref rid="R14" ref-type="bibr"><offsets xml_i="11463" xml_f="11465" txt_i="4477" txt_f="4479">14</offsets></xref><offsets xml_i="11472" xml_f="11473" txt_i="4479" txt_f="4480">,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="11505" xml_f="11507" txt_i="4480" txt_f="4482">16</offsets></xref><offsets xml_i="11514" xml_f="11515" txt_i="4482" txt_f="4483">,</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="11547" xml_f="11549" txt_i="4483" txt_f="4485">25</offsets></xref><offsets xml_i="11556" xml_f="11557" txt_i="4485" txt_f="4486">-</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="11589" xml_f="11591" txt_i="4486" txt_f="4488">27</offsets></xref></sup><offsets xml_i="11604" xml_f="11716" txt_i="4488" txt_f="4600"> We speculated that further CNI reduction, or even withdrawal, was needed to achieve renal function improvement.</offsets></p><p><offsets xml_i="11723" xml_f="11987" txt_i="4601" txt_f="4865">The rATG is usually administered as a series of small doses spaced at 1-day or 2-day intervals. However, more intensive administration (fewer, larger doses) may confer more comprehensive lymphocyte depletion, both peripherally and in secondary lymphoid structures.</offsets><sup><xref rid="R28" ref-type="bibr"><offsets xml_i="12024" xml_f="12026" txt_i="4865" txt_f="4867">28</offsets></xref></sup><offsets xml_i="12039" xml_f="12169" txt_i="4867" txt_f="4997"> Improved early renal function with deceased donor kidneys was reported when rATG administration was initiated before reperfusion,</offsets><sup><xref rid="R29" ref-type="bibr"><offsets xml_i="12206" xml_f="12208" txt_i="4997" txt_f="4999">29</offsets></xref></sup><offsets xml_i="12221" xml_f="12353" txt_i="4999" txt_f="5131"> and a nonrandomized experience with single-dose (SD) rATG induction seemed to enable CNI minimization and even complete withdrawal.</offsets><sup><xref rid="R30" ref-type="bibr"><offsets xml_i="12390" xml_f="12392" txt_i="5131" txt_f="5133">30</offsets></xref><offsets xml_i="12399" xml_f="12400" txt_i="5133" txt_f="5134">-</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="12432" xml_f="12434" txt_i="5134" txt_f="5136">33</offsets></xref></sup><offsets xml_i="12447" xml_f="12548" txt_i="5136" txt_f="5237"> Impressed by its possible benefits, we designed a randomized, nonblinded trial of SD rATG induction.</offsets></p><p><offsets xml_i="12555" xml_f="12751" txt_i="5238" txt_f="5434">The 2×2 factorial trial design we used, although uncommon in transplantation studies, has been recommended as resolving multiple hypotheses with a minimum investment of patients, time, and effort.</offsets><sup><xref rid="R34" ref-type="bibr"><offsets xml_i="12788" xml_f="12790" txt_i="5434" txt_f="5436">34</offsets></xref><offsets xml_i="12797" xml_f="12798" txt_i="5436" txt_f="5437">,</offsets><xref rid="R35" ref-type="bibr"><offsets xml_i="12830" xml_f="12832" txt_i="5437" txt_f="5439">35</offsets></xref></sup><offsets xml_i="12845" xml_f="13227" txt_i="5439" txt_f="5821"> This design allowed efficient detection of the independent effects of SD versus divided-dose (DD) rATG induction and CNI minimization versus withdrawal. The primary endpoints of the trial were renal function and protocol biopsy histopathology, with secondary endpoints that included patient, graft, and rejection-free survival, and infectious and noninfectious complications (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13257" xml_f="13258" txt_i="5821" txt_f="5822">1</offsets></xref><offsets xml_i="13265" xml_f="13267" txt_i="5822" txt_f="5824">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="13308" xml_f="13316" txt_i="5825" txt_f="5833">FIGURE 1</offsets></label><caption><p><offsets xml_i="13336" xml_f="14360" txt_i="5833" txt_f="6857">2×2 factorial trial of rATG induction dosing and CNI withdrawal. Between April 20, 2004, and April 14, 2009, at the University of Nebraska Medical Center, 180 recipients of renal transplants were enrolled in a single center, prospective, randomized, unblinded 2×2 factorial trial of single-dose versus divided-dose rATG induction (6 mg/kg over 24 hr vs. 1.5 mg/kg × 4 alternate-day doses) followed after 6 months by CNI minimization or CNI withdrawal and replacement with MMF (IRB # 286–03; ClinicalTrials.gov #NCT00556933). Two patients not meeting enrollment criteria were consented and randomized in error, but were identified before transplantation and removed from participation in the trial. Sirolimus introduction was delayed in favor of MMF use until weeks 3 to 6 in patients with ATN-DGF or who were at high risk for wound complications (e.g., truncal obesity). We determined that 160 patients would provide 80% power with a two-sided 0.05 α level to detect a 10% difference in calculated GFR during the first year.</offsets><sup><xref rid="R34" ref-type="bibr"><offsets xml_i="14397" xml_f="14399" txt_i="6857" txt_f="6859">34</offsets></xref></sup><offsets xml_i="14412" xml_f="15129" txt_i="6859" txt_f="7576"> (Enrollment was raised to 180 during the trial to guarantee sufficient patients to undergo eventual CNI withdrawal.) Randomization included stratification by race (white/Asian vs. non-white/Asian), donor type (living vs. deceased), and whether listed for eventual pancreas transplantation. Randomized assignments for both part 1 and part 2 treatment were contained in sequentially numbered, sealed envelopes opened after obtaining consent for trial participation to maintain allocation concealment. All analyses are intent-to-treat. MMF, mycophenolate mofetil; GFR, glomerular filtration rate; ATN, acute tubular necrosis; DGF, delayed graft function; rATG, rabbit antithymocyte globulin; CNI, calcineurin inhibitor.</offsets></p></caption><graphic xlink:href="tp-99-197-g001"></graphic></fig><p><offsets xml_i="15199" xml_f="16057" txt_i="7577" txt_f="8435">We previously reported the 6-month (part 1) interim results of this trial, showing the early tolerability of SD rATG induction and its association with superior (first week only) renal function among deceased donor recipients. However, this improvement did not sustain significance throughout the remainder of the initial 6-month analysis. Given that the average follow-up was less than 2 years, this initial report could not address the longer-term safety and efficacy of SD induction. In this article, we report the long-term results of part 1 of the trial, with increased enrollment and average follow-up over 4 years, enabling a robust assessment of longer-term safety and efficacy of induction with SD rATG. Part 2 of this 2×2 factorial trial, the long-term results of complete CNI withdrawal versus minimization, will be reported in a separate article.</offsets></p><sec sec-type="results"><title><offsets xml_i="16092" xml_f="16099" txt_i="8436" txt_f="8443">RESULTS</offsets></title><sec sec-type="subjects"><title><offsets xml_i="16139" xml_f="16197" txt_i="8444" txt_f="8502">Patient Enrollment and Recipient and Donor Characteristics</offsets></title><p><offsets xml_i="16208" xml_f="16356" txt_i="8503" txt_f="8651">Follow-up after transplantation averaged 51.8±15.1 months, with no patient followed less than 2 years. Patients excluded are presented in Table S1 (</offsets><bold><offsets xml_i="16362" xml_f="16365" txt_i="8651" txt_f="8654">SDC</offsets></bold><offsets xml_i="16372" xml_f="16374" txt_i="8654" txt_f="8656">, </offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="16445" xml_f="16472" txt_i="8656" txt_f="8683">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="16483" xml_f="16728" txt_i="8683" txt_f="8928">). Four previously transplanted patients were enrolled and distributed equally between the study arms. Patients were censored for reasons that included withdrawal of consent, scheduled pancreas transplantation, transfer of care, or death (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16760" xml_f="16761" txt_i="8928" txt_f="8929">1</offsets></xref><offsets xml_i="16768" xml_f="16773" txt_i="8929" txt_f="8934"> and </offsets><bold><offsets xml_i="16779" xml_f="16793" txt_i="8934" txt_f="8948">Table S1, SDC,</offsets></bold><offsets xml_i="16800" xml_f="16801" txt_i="8948" txt_f="8949">
</offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="16872" xml_f="16899" txt_i="8949" txt_f="8976">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="16910" xml_f="16971" txt_i="8976" txt_f="9037">). Causes of patient renal failure are detailed in Table S2 (</offsets><bold><offsets xml_i="16977" xml_f="16980" txt_i="9037" txt_f="9040">SDC</offsets></bold><offsets xml_i="16987" xml_f="16989" txt_i="9040" txt_f="9042">, </offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="17060" xml_f="17087" txt_i="9042" txt_f="9069">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="17098" xml_f="17100" txt_i="9069" txt_f="9071">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="17148" xml_f="17155" txt_i="9072" txt_f="9079">TABLE 1</offsets></label><caption><p><offsets xml_i="17175" xml_f="17224" txt_i="9079" txt_f="9128">Complications and infections after rATG induction</offsets></p></caption><graphic xlink:href="tp-99-197-g002"></graphic></table-wrap><p><offsets xml_i="17301" xml_f="17977" txt_i="9129" txt_f="9805">With the multiplicity of possible demographic comparisons, there was a 64% chance that at least one of the differences between the SD and DD groups would be significant when in fact no difference actually exists. To maintain the family-wise collective type-1 error rate over all 20 demographic comparisons at 0.05, a Bonferroni critical value adjustment was calculated for the individual tests, none of which were significant. Despite the lack of significant demographic differences between the trial arms, factors potentially impacting study outcomes have been included as covariates in all of our numerical modeling (e.g., patient age, pretransplant diabetes, hypertension).</offsets></p></sec><sec><title><offsets xml_i="17999" xml_f="18065" txt_i="9807" txt_f="9873">Analysis for Interaction Between rATG Induction and CNI Withdrawal</offsets></title><p><offsets xml_i="18076" xml_f="18353" txt_i="9874" txt_f="10151">Validation of the 2×2 trial design included numerical modeling of primary and secondary endpoints and possible covariates, which showed that CNI withdrawal status did not interact significantly with rATG induction regimen, justifying independent analysis of the two treatments.</offsets><sup><xref rid="R35" ref-type="bibr"><offsets xml_i="18390" xml_f="18392" txt_i="10151" txt_f="10153">35</offsets></xref></sup></p></sec><sec><title><offsets xml_i="18427" xml_f="18502" txt_i="10155" txt_f="10230">rATG and Steroid Exposure and Acute Tubular Necrosis-Delayed Graft Function</offsets></title><p><offsets xml_i="18513" xml_f="18621" txt_i="10231" txt_f="10339">The total rATG administered was similar between groups: induction (SD, 5.8±0.9 mg/kg vs. DD, 5.9±0.6 mg/kg; </offsets><italic><offsets xml_i="18629" xml_f="18630" txt_i="10339" txt_f="10340">P</offsets></italic><offsets xml_i="18639" xml_f="18786" txt_i="10340" txt_f="10487">=0.72) to treat acute tubular necrosis (ATN), delayed graft function (DGF), or poor early renal function (SD, 4.1±1.4 mg/kg vs. DD, 2.8±1.8 mg/kg; </offsets><italic><offsets xml_i="18794" xml_f="18795" txt_i="10487" txt_f="10488">P</offsets></italic><offsets xml_i="18804" xml_f="18872" txt_i="10488" txt_f="10556">=0.15) or cumulative dose (SD, 6.2±1.5 mg/kg vs. DD, 6.1±1.2 mg/kg; </offsets><italic><offsets xml_i="18880" xml_f="18881" txt_i="10556" txt_f="10557">P</offsets></italic><offsets xml_i="18890" xml_f="18968" txt_i="10557" txt_f="10635">=0.85). Total steroid exposure was SD, 12.2±2.9 mg/kg and DD, 12.1±2.4 mg/kg (</offsets><italic><offsets xml_i="18976" xml_f="18977" txt_i="10635" txt_f="10636">P</offsets></italic><offsets xml_i="18986" xml_f="18993" txt_i="10636" txt_f="10643">=0.84).</offsets></p><p><offsets xml_i="19000" xml_f="19163" txt_i="10644" txt_f="10807">All patients receiving additional rATG and steroid to treat ATN-DGF (n=12) or poor early renal function (n=5) received deceased donor kidneys (SD vs. DD, 9 vs. 8; </offsets><italic><offsets xml_i="19171" xml_f="19172" txt_i="10807" txt_f="10808">P</offsets></italic><offsets xml_i="19181" xml_f="19188" txt_i="10808" txt_f="10815">=0.55).</offsets></p></sec><sec><title><offsets xml_i="19210" xml_f="19295" txt_i="10817" txt_f="10902">Maintenance Immunosuppression, Therapeutic Drug Monitoring, and Antiviral Prophylaxis</offsets></title><p><offsets xml_i="19306" xml_f="19426" txt_i="10903" txt_f="11023">Because of obesity or ATN-DGF, MMF (instead of sirolimus) was in use at day 14 in 39 (44%) SD and 44 (49%) DD patients (</offsets><italic><offsets xml_i="19434" xml_f="19435" txt_i="11023" txt_f="11024">P</offsets></italic><offsets xml_i="19444" xml_f="19677" txt_i="11024" txt_f="11257">=0.55), with 90% of all patients being initiated on sirolimus by week 6. Only 5% of the patients proved unable to tolerate or afford sirolimus in the long term. Overall exposure to MMF was not statistically different between groups (</offsets><italic><offsets xml_i="19685" xml_f="19686" txt_i="11257" txt_f="11258">P</offsets></italic><offsets xml_i="19695" xml_f="19702" txt_i="11258" txt_f="11265">=0.99).</offsets></p><p><offsets xml_i="19709" xml_f="19990" txt_i="11266" txt_f="11547">Three of the 12 patients with ATN-DGF did not receive sirolimus; sirolimus was initiated in the remaining nine at 5 to 306 days (82±106). One sirolimus-free patient died on day 39; the remaining 11 all achieved a serum creatinine less than 3.0 mg/dL after 8 to 46 days (23.1±12.0).</offsets></p><p><offsets xml_i="19997" xml_f="20201" txt_i="11548" txt_f="11752">Mean immunosuppressant trough levels of both tacrolimus and sirolimus declined over time in accordance with the study design; however, levels tended to be at or just above the upper limit of the [target]:</offsets></p><table-wrap id="TU1" position="float"><graphic xlink:href="tp-99-197-g003"></graphic></table-wrap><p><offsets xml_i="20306" xml_f="20360" txt_i="11753" txt_f="11807">The combined tacrolimus+sirolimus levels (ng/mL) were:</offsets></p><table-wrap id="TU2" position="float"><graphic xlink:href="tp-99-197-g004"></graphic></table-wrap><p><offsets xml_i="20465" xml_f="20693" txt_i="11808" txt_f="12036">Actual sirolimus level among patients withdrawn from CNI: [8-12] 10.4±1.4, with an average MMF dose of 1.9±0.3 g per day. An equal number of patients underwent CNI withdrawal in each induction group (SD vs. DD, 32/89 vs. 33/89; </offsets><italic><offsets xml_i="20701" xml_f="20702" txt_i="12036" txt_f="12037">P</offsets></italic><offsets xml_i="20711" xml_f="20718" txt_i="12037" txt_f="12044">=1.00).</offsets></p><p><offsets xml_i="20725" xml_f="20871" txt_i="12045" txt_f="12191">Mean immunosuppressant trough levels and antiviral prophylaxis exposure were not statistically different between the induction groups at any time.</offsets></p></sec><sec><title><offsets xml_i="20893" xml_f="20907" txt_i="12193" txt_f="12207">Renal Function</offsets></title><p><offsets xml_i="20918" xml_f="20952" txt_i="12208" txt_f="12242">In contrast to our interim report,</offsets><sup><xref rid="R36" ref-type="bibr"><offsets xml_i="20989" xml_f="20991" txt_i="12242" txt_f="12244">36</offsets></xref></sup><offsets xml_i="21004" xml_f="21369" txt_i="12244" txt_f="12609"> we now show superior renal function among all patients and deceased donor recipients for 3 years after transplantation. We designed the trial to take full advantage of repeated serum creatinines collected throughout the follow-up (General Linear Model of repeated measures), but we can show superior renal function among SD patients months 36 to 38 (all patients, </offsets><italic><offsets xml_i="21377" xml_f="21378" txt_i="12609" txt_f="12610">P</offsets></italic><offsets xml_i="21387" xml_f="21421" txt_i="12610" txt_f="12644">=0.04; deceased donor recipients, </offsets><italic><offsets xml_i="21429" xml_f="21430" txt_i="12644" txt_f="12645">P</offsets></italic><offsets xml_i="21439" xml_f="21480" txt_i="12645" txt_f="12686">=0.06), but not living-donor recipients (</offsets><italic><offsets xml_i="21488" xml_f="21489" txt_i="12686" txt_f="12687">P</offsets></italic><offsets xml_i="21498" xml_f="21505" txt_i="12687" txt_f="12694">=0.35).</offsets></p></sec><sec><title><offsets xml_i="21527" xml_f="21584" txt_i="12696" txt_f="12753">Histopathology in 12-Month and 24-Month Protocol Biopsies</offsets></title><p><offsets xml_i="21595" xml_f="21966" txt_i="12754" txt_f="13125">At 12 months, rATG induction protocol had no independent effect on the five Banff categories of chronic renal injury (singly or together). There also was no difference in Banff scores for inflammation in areas of interstitial fibrosis or tubular atrophy or inflammation throughout the biopsy. Protocol biopsies collected at 24 months are presented only graphically (Fig. </offsets><xref ref-type="fig" rid="F2b"><offsets xml_i="21997" xml_f="21999" txt_i="13125" txt_f="13127">2B</offsets></xref><offsets xml_i="22006" xml_f="22008" txt_i="13127" txt_f="13129">).</offsets></p><fig id="F2a" position="float"><label><offsets xml_i="22050" xml_f="22058" txt_i="13130" txt_f="13138">FIGURE 2</offsets></label><caption><p><offsets xml_i="22078" xml_f="22153" txt_i="13138" txt_f="13213">A, Graft function was assessed by using the aMDRD equation to estimate GFR,</offsets><sup><xref rid="R57" ref-type="bibr"><offsets xml_i="22190" xml_f="22192" txt_i="13213" txt_f="13215">57</offsets></xref><offsets xml_i="22199" xml_f="22200" txt_i="13215" txt_f="13216">,</offsets><xref rid="R72" ref-type="bibr"><offsets xml_i="22232" xml_f="22234" txt_i="13216" txt_f="13218">72</offsets></xref></sup><offsets xml_i="22247" xml_f="22940" txt_i="13218" txt_f="13911"> using all blood draws that provided serum creatinine measurements. Greater blood draw frequency during the first 6 months allowed weekly averages for each group to be compared, followed by monthly averages after 6 months. The GFR between treatment groups was compared and analyzed using a general linear model for repeated measures with maximum likelihood estimation, an approach sensitive to differences between small groups despite large intrapatient variance over time. Ordinary least-squares regression was not used because in the context of repeated measures, it can fail to recognize significant effects in the model because of faulty estimation of the covariance structure of the data.</offsets><sup><xref rid="R75" ref-type="bibr"><offsets xml_i="22977" xml_f="22979" txt_i="13911" txt_f="13913">75</offsets></xref></sup><offsets xml_i="22992" xml_f="23111" txt_i="13913" txt_f="14032"> Although more patients in the single-dose group developed ATN-DGF, this trend did not reach statistical significance (</offsets><italic><offsets xml_i="23119" xml_f="23120" txt_i="14032" txt_f="14033">P</offsets></italic><offsets xml_i="23129" xml_f="23994" txt_i="14033" txt_f="14898">=0.11). This likely reflects our failure early in the trial to administer sufficient steroids to single-dose recipients; total steroid exposure, after our initial 20 patients, was increased from 6 mg/kg to 12 mg/kg. B, Frequencies for each induction group’s individual Banff categories were compared by Kruskal-Wallis rank testing. At 12 months, among single-dose recipients, there were five instances of suspicious or borderline rejection and nine among single-dose recipients. Among 24-month protocol biopsies, there were five instances of suspicious or borderline rejection in single-dose recipients and eight in the divided-dose group. There were no observations of recurrent disease among the protocol biopsies. aMDRD, abbreviated modification of diet in renal disease; GFR, glomerular filtration rate; ATN, acute tubular necrosis; DGF, delayed graft function.</offsets></p></caption><graphic xlink:href="tp-99-197-g005"></graphic></fig><fig id="F2b" position="float"><label><offsets xml_i="24099" xml_f="24107" txt_i="14899" txt_f="14907">FIGURE 2</offsets></label><caption><p><offsets xml_i="24127" xml_f="24138" txt_i="14907" txt_f="14918">(continued)</offsets></p></caption><graphic xlink:href="tp-99-197-g006"></graphic></fig></sec><sec sec-type="subjects"><title><offsets xml_i="24243" xml_f="24290" txt_i="14920" txt_f="14967">Patient Survival, Graft Survival, and Rejection</offsets></title><p><offsets xml_i="24301" xml_f="24446" txt_i="14968" txt_f="15113">There were significantly fewer deaths among kidney recipients who received SD rATG induction; causes of patient death are presented in Table S3 (</offsets><bold><offsets xml_i="24452" xml_f="24456" txt_i="15113" txt_f="15117">SDC,</offsets></bold><offsets xml_i="24463" xml_f="24464" txt_i="15117" txt_f="15118">
</offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="24535" xml_f="24562" txt_i="15118" txt_f="15145">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="24573" xml_f="24716" txt_i="15145" txt_f="15288">). No statistically significant differences were present between induction groups in death-censored or rejection-free graft survival (see Fig. </offsets><xref ref-type="fig" rid="F3a"><offsets xml_i="24747" xml_f="24749" txt_i="15288" txt_f="15290">3A</offsets></xref><offsets xml_i="24756" xml_f="24778" txt_i="15290" txt_f="15312">, Banff acute scores; </offsets><bold><offsets xml_i="24784" xml_f="24798" txt_i="15312" txt_f="15326">Table S3, SDC,</offsets></bold><offsets xml_i="24805" xml_f="24806" txt_i="15326" txt_f="15327">
</offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="24877" xml_f="24904" txt_i="15327" txt_f="15354">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="24915" xml_f="24917" txt_i="15354" txt_f="15356">).</offsets></p><fig id="F3a" position="float"><label><offsets xml_i="24959" xml_f="24967" txt_i="15357" txt_f="15365">FIGURE 3</offsets></label><caption><p><offsets xml_i="24987" xml_f="25287" txt_i="15365" txt_f="15665">A, Rates of patient survival, graft survival, and rejection were compared with Kaplan-Meier analyses and log-rank tests. Patient deaths occurred at an average of 2.3±1.4 years after transplantation, of causes that included myocardial infarction, cancer, sepsis, drug overdose, and pulmonary embolus (</offsets><bold><offsets xml_i="25293" xml_f="25307" txt_i="15665" txt_f="15679">Table S2, SDC,</offsets></bold><offsets xml_i="25314" xml_f="25315" txt_i="15679" txt_f="15680">
</offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="25386" xml_f="25413" txt_i="15680" txt_f="15707">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="25424" xml_f="25561" txt_i="15707" txt_f="15844">). Rejection was confirmed by ultrasound-guided biopsies (biopsy-proven acute rejection) graded according to Banff 1997 or 2005 criteria.</offsets><sup><xref rid="R73" ref-type="bibr"><offsets xml_i="25598" xml_f="25600" txt_i="15844" txt_f="15846">73</offsets></xref></sup><offsets xml_i="25613" xml_f="26277" txt_i="15846" txt_f="16510">. There were eight acute cellular rejection episodes in the single-dose group; five Banff grade IA, three grade IB. There were five cellular rejections in the divided-dose group; 1 grade IA, 3 grade IB, 1 grade IIA. B, There were eight episodes of suspicious or borderline rejection in each group not included. There were three instances of DSA+ AMR observed among our study patients, all in the divided-dose rATGgroup, at 9 days, 9months, and 14 months after transplantation. Only one of these grafts has been lost, at 2 years in the patient who experienced AMR at 14 months. The treatment of acute cellular rejection was guided by specific Banff classification (</offsets><bold><offsets xml_i="26283" xml_f="26297" txt_i="16510" txt_f="16524">Table S4, SDC,</offsets></bold><offsets xml_i="26304" xml_f="26305" txt_i="16524" txt_f="16525">
</offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="26376" xml_f="26403" txt_i="16525" txt_f="16552">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="26414" xml_f="27359" txt_i="16552" txt_f="17497">). (B) Kaplan-Meier estimates of likelihood of infection after rATG induction and renal transplantation. The first of any infection after transplantation was scored, including pneumonia, abscess, UTI, bacteremia, “other” bacterial, BK (viruria or disease),CMV, Epstein-Barr virus, post-transplantation lymphoproliferative disorder, “other” viral, and fungal. C, In both rATG induction groups, lymphocyte counts immediately declined steeply after rATG infusion, but recovered significantly more rapidly in the single-dose group. D and E, T-cell subset data were obtained from only the first 80 patients because of the cost. Although CD8 numbers recovered rapidly and equally in both groups, CD4 counts and the CD4-to-CD8 ratio recovered significantly faster in the single-dose group. DSA+, donor-specific antibody positive; AMR, antibody-mediated rejection; rATG, rabbit antithymocyte globulin; CMV, cytomegalovirus; UTI, urinary tract infection.</offsets></p></caption><graphic xlink:href="tp-99-197-g007"></graphic></fig><fig id="F3b" position="float"><label><offsets xml_i="27464" xml_f="27472" txt_i="17498" txt_f="17506">FIGURE 3</offsets></label><caption><p><offsets xml_i="27492" xml_f="27503" txt_i="17506" txt_f="17517">(continued)</offsets></p></caption><graphic xlink:href="tp-99-197-g008"></graphic></fig></sec><sec><title><offsets xml_i="27588" xml_f="27615" txt_i="17519" txt_f="17546">Noninfectious Complications</offsets></title><p><offsets xml_i="27626" xml_f="28014" txt_i="17547" txt_f="17935">Composited rATG infusion complication rates were not statistically different between induction groups. Hernias requiring repair were more frequent among DD patients. The frequency of hernia risk factors (e.g., age, body mass index, diabetes, sirolimus exposure) did not explain this difference. Interestingly, more patients with polycystic kidney disease were randomized to the DD group (</offsets><italic><offsets xml_i="28022" xml_f="28023" txt_i="17935" txt_f="17936">P</offsets></italic><offsets xml_i="28032" xml_f="28160" txt_i="17936" txt_f="18064">=0.012), but patients who developed hernias showed an equal incidence of polycystic kidney disease within each induction group (</offsets><italic><offsets xml_i="28168" xml_f="28169" txt_i="18064" txt_f="18065">P</offsets></italic><offsets xml_i="28178" xml_f="28192" txt_i="18065" txt_f="18079">=0.61) (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="28224" xml_f="28225" txt_i="18079" txt_f="18080">2</offsets></xref><offsets xml_i="28232" xml_f="28234" txt_i="18080" txt_f="18082">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="28282" xml_f="28289" txt_i="18083" txt_f="18090">TABLE 2</offsets></label><caption><p><offsets xml_i="28309" xml_f="28343" txt_i="18090" txt_f="18124">Complications after rATG induction</offsets></p></caption><graphic xlink:href="tp-99-197-g009"></graphic></table-wrap></sec><sec><title><offsets xml_i="28435" xml_f="28459" txt_i="18126" txt_f="18150">Infectious Complications</offsets></title><p><offsets xml_i="28470" xml_f="28477" txt_i="18151" txt_f="18158">Tables </offsets><xref ref-type="table" rid="T2"><offsets xml_i="28509" xml_f="28510" txt_i="18158" txt_f="18159">2</offsets></xref><offsets xml_i="28517" xml_f="28522" txt_i="18159" txt_f="18164"> and </offsets><xref ref-type="table" rid="T3"><offsets xml_i="28554" xml_f="28555" txt_i="18164" txt_f="18165">3</offsets></xref><offsets xml_i="28562" xml_f="28782" txt_i="18165" txt_f="18385"> summarize the most serious infections or infection sequelae (e.g., post-transplantation lymphoproliferative disorder [PTLD]). Thirty-four patients demonstrated serious infectious outcomes among 178 patients (19%), 73% (</offsets><italic><offsets xml_i="28790" xml_f="28791" txt_i="18385" txt_f="18386">P</offsets></italic><offsets xml_i="28800" xml_f="29080" txt_i="18386" txt_f="18663">&lt;0.001) of these were DD patients. Patients with abscesses or pneumonia are not included among those listed with bacteremia to avoid duplication of events; those with bacteremia had associated cardiopulmonary signs indicative of sepsis, typically from line sepsis or urosepsis.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="29128" xml_f="29135" txt_i="18664" txt_f="18671">TABLE 3</offsets></label><caption><p><offsets xml_i="29155" xml_f="29225" txt_i="18671" txt_f="18741">Organisms and sources of bacterial and fungal infectious complications</offsets></p></caption><graphic xlink:href="tp-99-197-g010"></graphic></table-wrap><p><offsets xml_i="29302" xml_f="29419" txt_i="18742" txt_f="18859">Donor-recipient cytomegalovirus (CMV) serostatus profiles were not statistically different between induction groups (</offsets><italic><offsets xml_i="29427" xml_f="29428" txt_i="18859" txt_f="18860">P</offsets></italic><offsets xml_i="29437" xml_f="29451" txt_i="18860" txt_f="18874">=0.28) (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="29483" xml_f="29484" txt_i="18874" txt_f="18875">1</offsets></xref><offsets xml_i="29491" xml_f="29827" txt_i="18875" txt_f="19211">). Cytomegalovirus infection or disease occurred exclusively in D+ and R− patients (9 and 48; 19%). Only one patient (DD) showed tissue-invasive CMV disease (enteritis/colitis); the remaining eight demonstrated CMV syndrome. Cases of PTLD, included here as sequelae of Epstein-Barr virus infection, were all monoclonal B-cell lymphomas.</offsets></p><p><offsets xml_i="29834" xml_f="29973" txt_i="19212" txt_f="19351">Frequencies of multiple infections (two or more infectious origins, e.g., bacterial, viral, fungal) were lower among SD patients (1 vs. 9; </offsets><italic><offsets xml_i="29981" xml_f="29982" txt_i="19351" txt_f="19352">P</offsets></italic><offsets xml_i="29991" xml_f="30237" txt_i="19352" txt_f="19598">=0.02). Time-to-first infection was significantly earlier after DD induction. There were more infections-per-patient among those in either group treated with additional rATG and steroid (n=21) for ATN-DGF or rejection; 1.1±0.31 versus 0.57±0.08 (</offsets><italic><offsets xml_i="30245" xml_f="30246" txt_i="19598" txt_f="19599">P</offsets></italic><offsets xml_i="30255" xml_f="30376" txt_i="19599" txt_f="19720">=0.03). Multiple infections (both life-threatening and others) were also more common after additional rATG; 38% vs. 13% (</offsets><italic><offsets xml_i="30384" xml_f="30385" txt_i="19720" txt_f="19721">P</offsets></italic><offsets xml_i="30394" xml_f="30537" txt_i="19721" txt_f="19861">&lt;0.01). After receiving additional rATG, DD patients developed more infections than those receiving the single dose (1.6±0.49 vs. 0.5±0.27; </offsets><italic><offsets xml_i="30545" xml_f="30546" txt_i="19861" txt_f="19862">P</offsets></italic><offsets xml_i="30555" xml_f="30562" txt_i="19862" txt_f="19869">=0.06).</offsets></p></sec><sec><title><offsets xml_i="30584" xml_f="30630" txt_i="19871" txt_f="19917">Immunological Impact of rATG Induction Regimen</offsets></title><p><offsets xml_i="30641" xml_f="31001" txt_i="19918" txt_f="20278">After induction, the rate of total lymphocyte recovery was significantly faster in SD patients. The projected return to preinduction values for patients receiving the single dose was 6 years, and double dose, 14 years. This difference was primarily because of the more rapid recovery of the CD4 (but not CD8) subset in patients receiving the single dose (Fig. </offsets><xref ref-type="fig" rid="F3b"><offsets xml_i="31032" xml_f="31036" txt_i="20278" txt_f="20282">3C-E</offsets></xref><offsets xml_i="31043" xml_f="31045" txt_i="20282" txt_f="20284">).</offsets></p></sec><sec><title><offsets xml_i="31067" xml_f="31130" txt_i="20286" txt_f="20349">Multivariate Analysis of Infectious Complications and Mortality</offsets></title><p><offsets xml_i="31141" xml_f="31224" txt_i="20350" txt_f="20433">In a multivariate regression model of infectious complications, SD rATG induction (</offsets><italic><offsets xml_i="31232" xml_f="31233" txt_i="20433" txt_f="20434">P</offsets></italic><offsets xml_i="31242" xml_f="31298" txt_i="20434" txt_f="20490">=0.046) and higher 12-month absolute lymphocyte counts (</offsets><italic><offsets xml_i="31306" xml_f="31307" txt_i="20490" txt_f="20491">P</offsets></italic><offsets xml_i="31316" xml_f="31535" txt_i="20491" txt_f="20710">=0.033) associated with significantly fewer occurrences of severe viral infection (CMV infection or disease, BK nephropathy, and PTLD). In this model, additional associates of severe viral infection were increased age (</offsets><italic><offsets xml_i="31543" xml_f="31544" txt_i="20710" txt_f="20711">P</offsets></italic><offsets xml_i="31553" xml_f="31586" txt_i="20711" txt_f="20744">=0.042), pretransplant diabetes (</offsets><italic><offsets xml_i="31594" xml_f="31595" txt_i="20744" txt_f="20745">P</offsets></italic><offsets xml_i="31604" xml_f="31634" txt_i="20745" txt_f="20775">=0.015), and additional rATG (</offsets><italic><offsets xml_i="31642" xml_f="31643" txt_i="20775" txt_f="20776">P</offsets></italic><offsets xml_i="31652" xml_f="31751" txt_i="20776" txt_f="20875">=0.047). The risk of multiple infections decreased in association with rising absolute CD4 counts (</offsets><italic><offsets xml_i="31759" xml_f="31760" txt_i="20875" txt_f="20876">P</offsets></italic><offsets xml_i="31769" xml_f="31789" txt_i="20876" txt_f="20896">=0.06) and CD4-CD8 (</offsets><italic><offsets xml_i="31797" xml_f="31798" txt_i="20896" txt_f="20897">P</offsets></italic><offsets xml_i="31807" xml_f="31814" txt_i="20897" txt_f="20904">=0.05).</offsets></p><table-wrap id="TU3" position="float"><graphic xlink:href="tp-99-197-g011"></graphic></table-wrap><p><offsets xml_i="31919" xml_f="31997" txt_i="20905" txt_f="20983">Univariate Cox hazard analyses of patient mortality resulted in the following:</offsets></p><p><offsets xml_i="32004" xml_f="32336" txt_i="20984" txt_f="21316">The six significant covariates were combined into Cox multivariate hazard models and sequentially analyzed for their incremental contributions to LR statistics (the estimation algorithm for hypertension or cardiovascular disease failed because of excessive prevalence). The final optimized model comprised four covariates; DD rATG (</offsets><italic><offsets xml_i="32344" xml_f="32345" txt_i="21316" txt_f="21317">P</offsets></italic><offsets xml_i="32354" xml_f="32379" txt_i="21317" txt_f="21342">=0.019), deceased donor (</offsets><italic><offsets xml_i="32387" xml_f="32388" txt_i="21342" txt_f="21343">P</offsets></italic><offsets xml_i="32397" xml_f="32425" txt_i="21343" txt_f="21371">=0.003), serious infection (</offsets><italic><offsets xml_i="32433" xml_f="32434" txt_i="21371" txt_f="21372">P</offsets></italic><offsets xml_i="32443" xml_f="32482" txt_i="21372" txt_f="21411">=0.0.018), and lower lymphocyte count (</offsets><italic><offsets xml_i="32490" xml_f="32491" txt_i="21411" txt_f="21412">P</offsets></italic><offsets xml_i="32500" xml_f="32651" txt_i="21412" txt_f="21563">=0.001), all significantly associated with more hazard of mortality. Patients with all four conditions showed a 27-fold increased likelihood of death (</offsets><italic><offsets xml_i="32659" xml_f="32660" txt_i="21563" txt_f="21564">P</offsets></italic><offsets xml_i="32669" xml_f="32679" txt_i="21564" txt_f="21574">=0.00002).</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="32729" xml_f="32739" txt_i="21577" txt_f="21587">DISCUSSION</offsets></title><p><offsets xml_i="32750" xml_f="32945" txt_i="21588" txt_f="21783">The earliest description of depleting lymphocytes in vivo with antilymphocyte serum was by Metchnikoff in 1899, and its impact on skin homograft survival in rats was reported by Woodruff in 1963.</offsets><sup><xref rid="R37" ref-type="bibr"><offsets xml_i="32982" xml_f="32984" txt_i="21783" txt_f="21785">37</offsets></xref><offsets xml_i="32991" xml_f="32992" txt_i="21785" txt_f="21786">,</offsets><xref rid="R38" ref-type="bibr"><offsets xml_i="33024" xml_f="33026" txt_i="21786" txt_f="21788">38</offsets></xref></sup><offsets xml_i="33039" xml_f="33139" txt_i="21788" txt_f="21888"> In 1966, Monaco reported that horse antidog serum reduced allograft rejection in transplanted dogs.</offsets><sup><xref rid="R39" ref-type="bibr"><offsets xml_i="33176" xml_f="33178" txt_i="21888" txt_f="21890">39</offsets></xref></sup><offsets xml_i="33191" xml_f="33289" txt_i="21890" txt_f="21988"> Najarian and Starzl effectively treated kidney rejection in humans with horse antihuman globulin.</offsets><sup><xref rid="R40" ref-type="bibr"><offsets xml_i="33326" xml_f="33328" txt_i="21988" txt_f="21990">40</offsets></xref><offsets xml_i="33335" xml_f="33336" txt_i="21990" txt_f="21991">,</offsets><xref rid="R41" ref-type="bibr"><offsets xml_i="33368" xml_f="33370" txt_i="21991" txt_f="21993">41</offsets></xref></sup><offsets xml_i="33383" xml_f="33461" txt_i="21993" txt_f="22071"> Kaden (1992-1998) reported less ATN-DGF after induction using rATG-Fresenius.</offsets><sup><xref rid="R42" ref-type="bibr"><offsets xml_i="33498" xml_f="33500" txt_i="22071" txt_f="22073">42</offsets></xref></sup><offsets xml_i="33513" xml_f="33778" txt_i="22073" txt_f="22338"> The efficacy of induction with a single 9 mg/kg bolus of rATG-Fresenius versus two 20-mg doses of basiliximab was supported by Kyllonen in work reported in 2007, and SD rATG induction before weaning recipients to CNI monotherapy was reported by Starzl and Shapiro.</offsets><sup><xref rid="R31" ref-type="bibr"><offsets xml_i="33815" xml_f="33817" txt_i="22338" txt_f="22340">31</offsets></xref><offsets xml_i="33824" xml_f="33825" txt_i="22340" txt_f="22341">,</offsets><xref rid="R33" ref-type="bibr"><offsets xml_i="33857" xml_f="33859" txt_i="22341" txt_f="22343">33</offsets></xref><offsets xml_i="33866" xml_f="33867" txt_i="22343" txt_f="22344">,</offsets><xref rid="R43" ref-type="bibr"><offsets xml_i="33899" xml_f="33901" txt_i="22344" txt_f="22346">43</offsets></xref></sup><offsets xml_i="33914" xml_f="34125" txt_i="22346" txt_f="22557"> In 2009, Kaden summarized a large retrospective experience of SD rATG-Fresenius compared against an unmatched historical control group and concluded that the DD showed worse patient survival and graft function.</offsets><sup><xref rid="R30" ref-type="bibr"><offsets xml_i="34162" xml_f="34164" txt_i="22557" txt_f="22559">30</offsets></xref></sup></p><p><offsets xml_i="34184" xml_f="34458" txt_i="22560" txt_f="22834">No previous randomized trial has compared SD versus DD rATG induction as we have, and despite its limitations (single-center, open-label, primarily low immunologic risk patients), our previous reports indicated superior early graft function, overall equivalent early safety,</offsets><sup><xref rid="R36" ref-type="bibr"><offsets xml_i="34495" xml_f="34497" txt_i="22834" txt_f="22836">36</offsets></xref></sup><offsets xml_i="34510" xml_f="34592" txt_i="22836" txt_f="22918"> reduced early hyperglycemia and hypomagnesemia, and delayed development of NODAT.</offsets><sup><xref rid="R44" ref-type="bibr"><offsets xml_i="34629" xml_f="34631" txt_i="22918" txt_f="22920">44</offsets></xref></sup><offsets xml_i="34644" xml_f="35135" txt_i="22920" txt_f="23411"> The long-term data now seem to show that SD rATG associates with superior patient survival, improved early (all donor types), and long-term deceased-donor graft function, fewer infections, and fewer multiple infections. Our trial was in retrospect not adequately powered to detect a difference in histopathology between induction groups, due both to a slower rate of chronic injury development than that reported previously and patient unwillingness to undergo protocol biopsy at 24 months.</offsets><sup><xref rid="R45" ref-type="bibr"><offsets xml_i="35172" xml_f="35174" txt_i="23411" txt_f="23413">45</offsets></xref><offsets xml_i="35181" xml_f="35182" txt_i="23413" txt_f="23414">,</offsets><xref rid="R46" ref-type="bibr"><offsets xml_i="35214" xml_f="35216" txt_i="23414" txt_f="23416">46</offsets></xref></sup></p><p><offsets xml_i="35236" xml_f="35679" txt_i="23417" txt_f="23860">We selected the 2×2 trial design to increase statistical power by avoiding a four-group analysis. Because the trial involves an initial treatment (rATG induction) followed by a second treatment (CNI withdrawal after six months), it is proper to analyze each treatment separately if there is no significant confounding interaction between treatments and patients receiving each treatment are distributed equally between groups, as is true here.</offsets><sup><xref rid="R34" ref-type="bibr"><offsets xml_i="35716" xml_f="35718" txt_i="23860" txt_f="23862">34</offsets></xref><offsets xml_i="35725" xml_f="35726" txt_i="23862" txt_f="23863">,</offsets><xref rid="R35" ref-type="bibr"><offsets xml_i="35758" xml_f="35760" txt_i="23863" txt_f="23865">35</offsets></xref></sup></p><p><offsets xml_i="35780" xml_f="36593" txt_i="23866" txt_f="24679">The unexpected mortality difference between rATG induction groups was not because of the differences in demographics or exposure to total rATG, steroid, maintenance agents (tacrolimus, sirolimus, MMF), or antiviral prophylaxis (valganciclovir). The possibility that alternate-day administration of steroids (vs. over 24 hr) might account for the increased incidence of serious infections, multiple infections, and increased infections and mortality observed in the divided dose group is extremely unlikely in that the lymphocyte, CD4, and CD4-CD8 recovery rates that probably cause those outcomes are acutely and chronically influenced by rATG but not steroid administration. In our interim report, we did not observe any statistically significant differences in early complication rates between induction groups.</offsets><sup><xref rid="R36" ref-type="bibr"><offsets xml_i="36630" xml_f="36632" txt_i="24679" txt_f="24681">36</offsets></xref></sup></p><p><offsets xml_i="36652" xml_f="37265" txt_i="24682" txt_f="25295">The increased mortality among DD patients is consistent with that group’s increased infections, multiple infections, and more severe and prolonged CD4 T-cell depletion. The risk of multiple infections associated with the severity of CD4 T-cell lymphopenia, and in a multivariate regression model of infectious complications, SD rATG induction associated with higher 12-month absolute lymphocyte counts and significantly fewer occurrences of severe viral infection. An association has been shown between increased infections, mortality, morbidity, and the extent and duration of CD4 depletion after rATG induction.</offsets><sup><xref rid="R47" ref-type="bibr"><offsets xml_i="37302" xml_f="37304" txt_i="25295" txt_f="25297">47</offsets></xref></sup><offsets xml_i="37317" xml_f="37473" txt_i="25297" txt_f="25453"> Of the seven deaths among our DD rATG patients, most were from sepsis (43%) or cancer (29%), an outcome consistent with the observations of Ducloux et al.,</offsets><sup><xref rid="R47" ref-type="bibr"><offsets xml_i="37510" xml_f="37512" txt_i="25453" txt_f="25455">47</offsets></xref></sup><offsets xml_i="37525" xml_f="37646" txt_i="25455" txt_f="25576"> “….prolonged polyclonal anti-thymocyte globulin–induced CD4 T-cell lymphopenia is an independent risk factor for death (</offsets><italic><offsets xml_i="37654" xml_f="37655" txt_i="25576" txt_f="25577">P</offsets></italic><offsets xml_i="37664" xml_f="37799" txt_i="25577" txt_f="25712">=0.001)”. In renal transplant patients, fewer CD4-to-CD8 ratio because of any origin increased the risk of life-threatening infections.</offsets><sup><xref rid="R48" ref-type="bibr"><offsets xml_i="37836" xml_f="37838" txt_i="25712" txt_f="25714">48</offsets></xref></sup></p><p><offsets xml_i="37858" xml_f="38220" txt_i="25715" txt_f="26077">Four patients in the divided dose group showed cardiac complications of a significant arrhythmia or myocardial infarction as compared to one patient in the SD group. Interestingly, lymphopenia, especially CD4 lymphopenia, also has been associated with accelerated progression of coronary atherosclerosis and cardiac-related mortality after renal transplantation.</offsets><sup><xref rid="R49" ref-type="bibr"><offsets xml_i="38257" xml_f="38259" txt_i="26077" txt_f="26079">49</offsets></xref><offsets xml_i="38266" xml_f="38267" txt_i="26079" txt_f="26080">-</offsets><xref rid="R51" ref-type="bibr"><offsets xml_i="38299" xml_f="38301" txt_i="26080" txt_f="26082">51</offsets></xref></sup></p><p><offsets xml_i="38321" xml_f="38581" txt_i="26083" txt_f="26343">Alemtuzumab induction also has a profound and prolonged impact on lymphocyte populations. A review of more than 7,000 deceased donor renal transplants in the SRTR database indicated increased graft loss and patient death with alemtuzumab versus rATG induction.</offsets><sup><xref rid="R52" ref-type="bibr"><offsets xml_i="38618" xml_f="38620" txt_i="26343" txt_f="26345">52</offsets></xref></sup><offsets xml_i="38633" xml_f="38752" txt_i="26345" txt_f="26464"> However, in a prospective, randomized trial comparing alemtuzumab and rATG induction, no such difference was observed.</offsets><sup><xref rid="R53" ref-type="bibr"><offsets xml_i="38789" xml_f="38791" txt_i="26464" txt_f="26466">53</offsets></xref></sup><offsets xml_i="38804" xml_f="39031" txt_i="26466" txt_f="26693"> This difference may reflect the administration of two doses of alemtuzumab to most of the patients in the SRTR data set and the current practice of SD alemtuzumab induction in the patients in the prospective, randomized trial.</offsets></p><p><offsets xml_i="39038" xml_f="39137" txt_i="26694" txt_f="26793">The total exposure to rATG in this study was in keeping with that used at many transplant programs.</offsets><sup><xref rid="R25" ref-type="bibr"><offsets xml_i="39174" xml_f="39176" txt_i="26793" txt_f="26795">25</offsets></xref><offsets xml_i="39183" xml_f="39184" txt_i="26795" txt_f="26796">-</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="39216" xml_f="39218" txt_i="26796" txt_f="26798">27</offsets></xref></sup><offsets xml_i="39231" xml_f="39465" txt_i="26798" txt_f="27032"> An equal number of patients in each of our induction groups received additional rATG (ATN-DGF, poor early function, rejection), yet still there were more serious infections in the DD rATG group, suggesting greater immune suppression.</offsets></p><p><offsets xml_i="39472" xml_f="39670" txt_i="27033" txt_f="27231">How could administering rATG as a single dose produce the benefit to function we are reporting here? Given the polyclonal nature of rATG, this effect may not be directly related to T-cell depletion.</offsets><sup><xref rid="R54" ref-type="bibr"><offsets xml_i="39707" xml_f="39709" txt_i="27231" txt_f="27233">54</offsets></xref><offsets xml_i="39716" xml_f="39717" txt_i="27233" txt_f="27234">,</offsets><xref rid="R55" ref-type="bibr"><offsets xml_i="39749" xml_f="39751" txt_i="27234" txt_f="27236">55</offsets></xref></sup><offsets xml_i="39764" xml_f="39993" txt_i="27236" txt_f="27465"> For example, investigators have identified rATG antibodies with affinities to endovascular adhesion molecules necessary to leukocyte homing and trafficking, suggesting that rATG may be able to reduce ischemia-reperfusion injury.</offsets><sup><xref rid="R7" ref-type="bibr"><offsets xml_i="40029" xml_f="40030" txt_i="27465" txt_f="27466">7</offsets></xref><offsets xml_i="40037" xml_f="40038" txt_i="27466" txt_f="27467">,</offsets><xref rid="R56" ref-type="bibr"><offsets xml_i="40070" xml_f="40072" txt_i="27467" txt_f="27469">56</offsets></xref><offsets xml_i="40079" xml_f="40080" txt_i="27469" txt_f="27470">-</offsets><xref rid="R61" ref-type="bibr"><offsets xml_i="40112" xml_f="40114" txt_i="27470" txt_f="27472">61</offsets></xref></sup><offsets xml_i="40127" xml_f="40162" txt_i="27472" txt_f="27507"> A recent report by Urbanova et al.</offsets><sup><xref rid="R62" ref-type="bibr"><offsets xml_i="40199" xml_f="40201" txt_i="27507" txt_f="27509">62</offsets></xref></sup><offsets xml_i="40214" xml_f="40722" txt_i="27509" txt_f="28017"> showed that 3 months after induction, thymoglobulin rATG, in contrast to rATG-Fresenius, decreased the expression of genes involved in the nuclear factor-kappa B (NF-κB) pathway (TLR4, MYD88, and CD209), along with CD80 and CTLA4 (costimulation), NLRP1 (apoptosis), CCR10 (chemoattraction), and CLEC4C (dendritic cell function). In an experimental model of kidney reperfusion injury, NF-κB upregulation correlated with the severity of injury, and inhibitors and antagonists of NF-κB had a beneficial effect.</offsets><sup><xref rid="R63" ref-type="bibr"><offsets xml_i="40759" xml_f="40761" txt_i="28017" txt_f="28019">63</offsets></xref><offsets xml_i="40768" xml_f="40769" txt_i="28019" txt_f="28020">,</offsets><xref rid="R64" ref-type="bibr"><offsets xml_i="40801" xml_f="40803" txt_i="28020" txt_f="28022">64</offsets></xref></sup><offsets xml_i="40816" xml_f="40941" txt_i="28022" txt_f="28147"> These findings suggest that rATG may have an impact on early renal allograft inflammation, and that this impact may persist.</offsets></p><p><offsets xml_i="40948" xml_f="41097" txt_i="28148" txt_f="28297">We have also found that up to 10% of rATG antibodies recognize and inactivate heparanase, and another 5% recognize and inactivate interleukin (IL)-2.</offsets><sup><xref rid="R44" ref-type="bibr"><offsets xml_i="41134" xml_f="41136" txt_i="28297" txt_f="28299">44</offsets></xref></sup><offsets xml_i="41149" xml_f="41405" txt_i="28299" txt_f="28555"> Heparanase in the kidney, released with reperfusion, degrades basement membrane heparan sulfate, allowing edema and cell infiltration. Extensive loss of heparan sulfate chains occurs within minutes of reperfusing rodent autocardiac and xenocardiac grafts.</offsets><sup><xref rid="R65" ref-type="bibr"><offsets xml_i="41442" xml_f="41444" txt_i="28555" txt_f="28557">65</offsets></xref><offsets xml_i="41451" xml_f="41452" txt_i="28557" txt_f="28558">,</offsets><xref rid="R66" ref-type="bibr"><offsets xml_i="41484" xml_f="41486" txt_i="28558" txt_f="28560">66</offsets></xref></sup><offsets xml_i="41499" xml_f="41550" txt_i="28560" txt_f="28611"> Because hypoxia upregulates heparanase expression,</offsets><sup><xref rid="R67" ref-type="bibr"><offsets xml_i="41587" xml_f="41589" txt_i="28611" txt_f="28613">67</offsets></xref></sup><offsets xml_i="41602" xml_f="41805" txt_i="28613" txt_f="28816"> ischemic organs may be “primed” to release heparanase. In addition to degrading the endothelial cell glycocalyx, heparanase releases heparan sulfate-bound IL-2 found in tissues and lining blood vessels.</offsets><sup><xref rid="R68" ref-type="bibr"><offsets xml_i="41842" xml_f="41844" txt_i="28816" txt_f="28818">68</offsets></xref><offsets xml_i="41851" xml_f="41852" txt_i="28818" txt_f="28819">,</offsets><xref rid="R69" ref-type="bibr"><offsets xml_i="41884" xml_f="41886" txt_i="28819" txt_f="28821">69</offsets></xref></sup><offsets xml_i="41899" xml_f="42014" txt_i="28821" txt_f="28936"> Local increases in IL-2 induce lymphocyte proliferation, neutrophil activation, and endothelial cell permeability.</offsets><sup><xref rid="R70" ref-type="bibr"><offsets xml_i="42051" xml_f="42053" txt_i="28936" txt_f="28938">70</offsets></xref><offsets xml_i="42060" xml_f="42061" txt_i="28938" txt_f="28939">,</offsets><xref rid="R71" ref-type="bibr"><offsets xml_i="42093" xml_f="42095" txt_i="28939" txt_f="28941">71</offsets></xref></sup></p><p><offsets xml_i="42115" xml_f="42395" txt_i="28942" txt_f="29222">The idea that the benefit of rATG induction in reducing inflammation or reperfusion injury might be dose-related is supported by an observation reported in our initial article that the amount of rATG administered before kidney reperfusion associated with improved renal function (</offsets><italic><offsets xml_i="42403" xml_f="42404" txt_i="29222" txt_f="29223">P</offsets></italic><offsets xml_i="42413" xml_f="42544" txt_i="29223" txt_f="29354">=0.025) (but not less ATN-DGF) during the first 5 days posttransplantation. (SD group vs. DD group, 0.61±0.26 vs. 0.16±0.06 mg/kg; </offsets><italic><offsets xml_i="42552" xml_f="42553" txt_i="29354" txt_f="29355">P</offsets></italic><offsets xml_i="42562" xml_f="42574" txt_i="29355" txt_f="29364">&lt;0.0001).</offsets><sup><xref rid="R36" ref-type="bibr"><offsets xml_i="42611" xml_f="42613" txt_i="29364" txt_f="29366">36</offsets></xref></sup><offsets xml_i="42626" xml_f="42642" txt_i="29366" txt_f="29382"> Kyllonen et al.</offsets><sup><xref rid="R31" ref-type="bibr"><offsets xml_i="42679" xml_f="42681" txt_i="29382" txt_f="29384">31</offsets></xref></sup><offsets xml_i="42694" xml_f="42841" txt_i="29384" txt_f="29531"> reported a significant reduction in ATN-DGF rates when the full rATG induction dose (9 mg/kg, rATG-Fresenius) was administered before reperfusion.</offsets></p><p><offsets xml_i="42848" xml_f="43344" txt_i="29532" txt_f="30028">We hypothesize that SD rATG induction results in a higher concentration of rATG at reperfusion, and more extensively decreases NF-κB and blocks adhesion molecules, heparanase, and IL-2 that are undoubtedly expressed and released to a greater extent in deceased donor kidneys. This hypothesis is consistent with the greater benefit to renal function of SD rATG in deceased versus living-donor kidneys and is undergoing direct evaluation in our ongoing STAT multicenter clinical trial (STAT trial; </offsets><italic><offsets xml_i="43352" xml_f="43353" txt_i="30028" txt_f="30029">S</offsets></italic><offsets xml_i="43362" xml_f="43377" txt_i="30029" txt_f="30044">ingle-dose vs. </offsets><italic><offsets xml_i="43385" xml_f="43386" txt_i="30044" txt_f="30045">T</offsets></italic><offsets xml_i="43395" xml_f="43406" txt_i="30045" txt_f="30056">raditional </offsets><italic><offsets xml_i="43414" xml_f="43415" txt_i="30056" txt_f="30057">A</offsets></italic><offsets xml_i="43424" xml_f="43438" txt_i="30057" txt_f="30071">dministration </offsets><italic><offsets xml_i="43446" xml_f="43447" txt_i="30071" txt_f="30072">T</offsets></italic><offsets xml_i="43456" xml_f="43496" txt_i="30072" txt_f="30112">hymoglobulin) (Trials.gov #NCT00906204).</offsets></p><p><offsets xml_i="43503" xml_f="43801" txt_i="30113" txt_f="30411">In summary, the results from Part 1 of our 2×2 factorial trial suggest that rATG dosing strategy impacts both the safety and efficacy of lytic induction in renal transplantation. Both strategies of rATG induction at the least allow minimization of CNI and mTORi to the levels achieved in the trial.</offsets></p><p><offsets xml_i="43808" xml_f="43842" txt_i="30412" txt_f="30446">Our data support the concept that </offsets><italic><offsets xml_i="43850" xml_f="43853" txt_i="30446" txt_f="30449">how</offsets></italic><offsets xml_i="43862" xml_f="44184" txt_i="30449" txt_f="30771"> rATG is administered has an effect on its complication profile. However, an ironclad cause-and-effect relationship cannot be established because neither patient survival nor infection rates were used to power this trial. Our observations warrant definitive assessment in a larger, appropriately powered multicenter trial.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="44235" xml_f="44256" txt_i="30773" txt_f="30794">MATERIALS AND METHODS</offsets></title><sec sec-type="subjects"><title><offsets xml_i="44296" xml_f="44324" txt_i="30795" txt_f="30823">Study Patients and Endpoints</offsets></title><p><offsets xml_i="44335" xml_f="44734" txt_i="30824" txt_f="31223">Adult primary and selected previous renal transplant recipients (nonimmunologic causes of graft loss) over age 18 years were eligible for study participation. Patients excluded were: older than 65 years, panel-reactive antibodies greater than 75%, human leukocyte antigen-identical, or required steroids. Expanded-criteria donors and donation after cardiac death donors were excluded from the trial.</offsets></p><p><offsets xml_i="44741" xml_f="44871" txt_i="31224" txt_f="31354">Primary endpoints were renal function by calculated glomerular filtration rate (abbreviated modification of diet in renal disease)</offsets><sup><xref rid="R72" ref-type="bibr"><offsets xml_i="44908" xml_f="44910" txt_i="31354" txt_f="31356">72</offsets></xref></sup><offsets xml_i="44923" xml_f="45133" txt_i="31356" txt_f="31566"> and acute and chronic renal histopathology (based on Banff ’05 criteria). Secondary endpoints included patient survival, graft survival, biopsy-proven rejection, and infectious and noninfectious complications.</offsets></p></sec><sec sec-type="subjects"><title><offsets xml_i="45175" xml_f="45228" txt_i="31568" txt_f="31621">Power Analysis, Statistics, and Patient Randomization</offsets></title><p><offsets xml_i="45239" xml_f="45281" txt_i="31622" txt_f="31664">The power analysis is described in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="45311" xml_f="45312" txt_i="31664" txt_f="31665">1</offsets></xref><offsets xml_i="45319" xml_f="45521" txt_i="31665" txt_f="31867">. Individual figures and tables include details of statistical analyses. PASS software (NCSS LLC, Kaysville, UT), SAS software (SAS Institute, Cary, NC), and SPSS software (IBM Corporation, Armonk, NY).</offsets></p></sec><sec><title><offsets xml_i="45543" xml_f="45596" txt_i="31869" txt_f="31922">Assessment of Graft Function and Renal Histopathology</offsets></title><p><offsets xml_i="45607" xml_f="45661" txt_i="31923" txt_f="31977">Details are presented in the respective legends (Fig. </offsets><xref ref-type="fig" rid="F2a"><offsets xml_i="45692" xml_f="45694" txt_i="31977" txt_f="31979">2A</offsets></xref><offsets xml_i="45701" xml_f="45706" txt_i="31979" txt_f="31984"> and </offsets><xref ref-type="fig" rid="F2b"><offsets xml_i="45737" xml_f="45738" txt_i="31984" txt_f="31985">B</offsets></xref><offsets xml_i="45745" xml_f="45747" txt_i="31985" txt_f="31987">).</offsets></p></sec><sec><title><offsets xml_i="45769" xml_f="45809" txt_i="31989" txt_f="32029">rATG and Steroids; Induction and ATN-DGF</offsets></title><p><offsets xml_i="45820" xml_f="46017" txt_i="32030" txt_f="32227">All recipients received 6 mg/kg intravenous rATG (Genzyme Corporation, Cambridge, MA) beginning at transplantation, a single infusion over 24 hr or four 1.5 mg/kg infusions on alternate days (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="46047" xml_f="46048" txt_i="32227" txt_f="32228">1</offsets></xref><offsets xml_i="46055" xml_f="46057" txt_i="32228" txt_f="32230">).</offsets><sup><xref rid="R36" ref-type="bibr"><offsets xml_i="46094" xml_f="46096" txt_i="32230" txt_f="32232">36</offsets></xref></sup><offsets xml_i="46109" xml_f="46225" txt_i="32232" txt_f="32348"> The total steroid administered was 12 mg/kg, in 3 mg/kg doses with DD rATG, and 3 mg/kg Q6 over 24 hr with SD rATG.</offsets></p><p><offsets xml_i="46232" xml_f="46556" txt_i="32349" txt_f="32673">Except to treat rejection, steroids were administered only in association with rATG. In cases of ATN-DGF (dialysis within seven days of transplantation), up to six additional 1 mg/kg doses of rATG (with 1 mg/kg methylprednisolone) were given. To prevent excessive exposure to rATG and steroids, we capped exposure at 100 kg.</offsets></p></sec><sec><title><offsets xml_i="46578" xml_f="46608" txt_i="32675" txt_f="32705">Maintenance Immune Suppression</offsets></title><p><offsets xml_i="46619" xml_f="47203" txt_i="32706" txt_f="33284">Discretionary clinical judgment is required to achieve the best sequence and rate of introduction of maintenance agents to suit each patient’s circumstances. Initiating tacrolimus and sirolimus depends partly on early renal graft function. In patients with ATN-DGF, monotherapy with MMF (500 mg orally, two times per day) is initiated early (POD 1-3) and is replaced with CNI and sirolimus when graft function improves (sCr&lt;3.0). Similarly, in obese patients (BMI&gt;32 or truncal obesity), MMF is used until sirolimus can safely be initiated (3-6 weeks). Target blood levels were:</offsets></p><table-wrap id="TU4" position="float"><graphic xlink:href="tp-99-197-g012"></graphic></table-wrap><p><offsets xml_i="47308" xml_f="47365" txt_i="33285" txt_f="33342">Combined tacrolimus+sirolimus target levels [ng/mL] were:</offsets></p><table-wrap id="TU5" position="float"><graphic xlink:href="tp-99-197-g013"></graphic></table-wrap><p><offsets xml_i="47470" xml_f="47609" txt_i="33343" txt_f="33482">Patients who underwent CNI withdrawal after six months received MMF (1 g two times per day) with a sirolimus target level of 8 to 12 ng/mL.</offsets></p><p><offsets xml_i="47616" xml_f="47894" txt_i="33483" txt_f="33761">Although never formally validated, adding blood levels of the two maintenance agents was performed to avoid both agents being at the low end of their targeted range, thereby preventing the combined exposure from being inadequate in the context of ESW, a practice used by others.</offsets><sup><xref rid="R27" ref-type="bibr"><offsets xml_i="47931" xml_f="47933" txt_i="33761" txt_f="33763">27</offsets></xref></sup></p></sec><sec><title><offsets xml_i="47968" xml_f="48011" txt_i="33765" txt_f="33808">Viral, Fungal, and Pneumocystis Prophylaxis</offsets></title><p><offsets xml_i="48022" xml_f="48309" txt_i="33809" txt_f="34096">All recipients received oral valganciclovir and clotrimazole for 3 months after transplantation; CMV− recipients with a CMV+ donor received valganciclovir 3 months longer. Patients treated with rATG for rejection received a repeated course of the antiviral prophylaxis used at induction.</offsets></p><p><offsets xml_i="48316" xml_f="48517" txt_i="34097" txt_f="34298">Pneumocystis prophylaxis was with trimethoprim-sulfamethoxazole or, if allergic to sulfa, diamino-diphenyl sulfone (Dapsone) or aerosolized pentamidine diisethionate for 3 months after transplantation.</offsets></p></sec><sec><title><offsets xml_i="48539" xml_f="48568" txt_i="34300" txt_f="34329">CMV and BK Viral Surveillance</offsets></title><p><offsets xml_i="48579" xml_f="49345" txt_i="34330" txt_f="35093">In CMV− recipients transplanted with kidneys from CMV+ donors, blood viral DNA load was checked at 2 weeks, and then monthly for 6 months after valganciclovir was discontinued. Patients with significant leukopenia (white blood cells&lt;2,000) were routinely screened for CMV viremia or infection. All patients underwent urine screening for BK virus at months 1, 3, 6, 9, and 12, and then annually for 5 years. If urine screening showed more than 9 million viral DNA copies, blood was screened also. Patients with renal dysfunction and BK viremia underwent renal biopsy; asymptomatic patients with BK viremia more than 2,000 plasma BK DNA copies per milliliter also were biopsied. This threshold for significant BK viremia is higher than that now used by the authors.</offsets></p></sec><sec><title><offsets xml_i="49367" xml_f="49403" txt_i="35095" txt_f="35131">Diagnosis and Treatment of Rejection</offsets></title><p><offsets xml_i="49414" xml_f="49548" txt_i="35132" txt_f="35266">Rejection was confirmed by ultrasound-guided biopsies (biopsy-proven acute rejection) graded according to Banff 1997 or 2005 criteria.</offsets><sup><xref rid="R73" ref-type="bibr"><offsets xml_i="49585" xml_f="49587" txt_i="35266" txt_f="35268">73</offsets></xref></sup><offsets xml_i="49600" xml_f="49673" txt_i="35268" txt_f="35341"> The treatment of rejection was guided by specific Banff classification (</offsets><bold><offsets xml_i="49679" xml_f="49692" txt_i="35341" txt_f="35354">Table S4, SDC</offsets></bold><offsets xml_i="49699" xml_f="49701" txt_i="35354" txt_f="35356">, </offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="49772" xml_f="49799" txt_i="35356" txt_f="35383">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="49810" xml_f="49812" txt_i="35383" txt_f="35385">).</offsets></p></sec><sec><title><offsets xml_i="49834" xml_f="49876" txt_i="35387" txt_f="35429">Assessment of Complications and Infections</offsets></title><p><offsets xml_i="49887" xml_f="49932" txt_i="35430" txt_f="35475">Specific criteria defined each complication (</offsets><bold><offsets xml_i="49938" xml_f="49951" txt_i="35475" txt_f="35488">Table S5, SDC</offsets></bold><offsets xml_i="49958" xml_f="49960" txt_i="35488" txt_f="35490">, </offsets><ext-link ext-link-type="uri" xlink:href="http://links.lww.com/TP/B12"><offsets xml_i="50031" xml_f="50058" txt_i="35490" txt_f="35517">http://links.lww.com/TP/B12</offsets></ext-link><offsets xml_i="50069" xml_f="50421" txt_i="35517" txt_f="35869">). Complications were analyzed both individually and as sets occurring after rATG induction, early (rATG reaction, cardiac dysrhythmia, myocardial infarction, and serum sickness) or late (wound complications, lymphocele drainage, and hernia repair). Transplant infectious disease specialists (A.K. and D.F.) assessed infections using standard criteria.</offsets></p></sec></sec><sec sec-type="supplementary-material"><title><offsets xml_i="50483" xml_f="50505" txt_i="35872" txt_f="35894">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="SD1"><caption><title><offsets xml_i="50588" xml_f="50610" txt_i="35895" txt_f="35917">SUPPLEMENTARY MATERIAL</offsets></title></caption><media mimetype="document" mime-subtype="doc" xlink:href="tp-99-197-s001.doc" xlink:type="simple" id="d35e1063" position="anchor"></media></supplementary-material></sec></body><back><fn-group><fn fn-type="supported-by"><p>This work was supported by the Ann Goldstein-Cheryl Cooper New Frontiers in Transplant Medicine Fund, a Research Support Fund grant from the Nebraska Medical Center and the University of Nebraska Medical Center, and a research grant fromGenzyme Corporation, which partially funded clinical research nurse time.</p></fn><fn fn-type="conflict"><p>The authors declare no conflicts of interest.</p></fn><fn fn-type="other"><p>The trial reported in this article is registered at ClinicalTrials.gov, #NCT00556933.</p></fn><fn fn-type="participating-researchers"><p>R.B.S. designed and supervised the trial. K.W.F. read the study protocol biopsies. C.D.M. participated in the medical management of study patients and data review. J.T.L. participated in medical management of study patients and data review. A.C.K. reviewed and analyzed infectious complications of study patients. D.F.F. reviewed infectious complications of study patients. J.P.S. performed the statistical analyses. T.H.R. participated in chart review, data collection, article preparation, and editing. K.J.N. participated in study database management. J.Y.S. participated in chart review, data collection, and article preparation. A.M.K. maintained IRB documents. T.M. participated in patient management and article review. L.E.W. participated in data and article review, patient management, and heparan sulfate studies.</p></fn><fn fn-type="supplementary-material"><p>Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (<ext-link ext-link-type="uri" xlink:href="http://www.transplantjournal.com">www.transplantjournal.com</ext-link>).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kasiske</surname><given-names>BL</given-names></name><name><surname>Gaston</surname><given-names>RS</given-names></name><name><surname>Gourishankar</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Long-term deterioration of kidney allograft function</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2005</year>;
<volume>5</volume>:
<fpage>1405</fpage>.<pub-id pub-id-type="pmid">15888048</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal">
<person-group><name><surname>Flechner</surname><given-names>SM</given-names></name><name><surname>Kobashigawa</surname><given-names>J</given-names></name><name><surname>Klintmalm</surname><given-names>G</given-names></name></person-group>
<article-title>Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity</article-title>.
<source><italic>Clin Transplant</italic></source>
<year>2008</year>;
<volume>22</volume>:
<fpage>1</fpage>.<pub-id pub-id-type="pmid">18217899</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group><name><surname>Gaston</surname><given-names>RS</given-names></name><name><surname>Cecka</surname><given-names>JM</given-names></name><name><surname>Kasiske</surname><given-names>BL</given-names></name><etal></etal></person-group>
<article-title>Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure</article-title>.
<source><italic>Transplantation</italic></source>
<year>2010</year>;
<volume>90</volume>:
<fpage>68</fpage>.<pub-id pub-id-type="pmid">20463643</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group><name><surname>Haririan</surname><given-names>A</given-names></name><name><surname>Kiangkitiwan</surname><given-names>B</given-names></name><name><surname>Kukuruga</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>2758</fpage>.<pub-id pub-id-type="pmid">19845596</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group><name><surname>Hidalgo</surname><given-names>LG</given-names></name><name><surname>Campbell</surname><given-names>PM</given-names></name><name><surname>Sis</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>2532</fpage>.<pub-id pub-id-type="pmid">19843031</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kedainis</surname><given-names>RL</given-names></name><name><surname>Koch</surname><given-names>MJ</given-names></name><name><surname>Brennan</surname><given-names>DC</given-names></name><etal></etal></person-group>
<article-title>Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>812</fpage>.<pub-id pub-id-type="pmid">19344468</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group><name><surname>Einecke</surname><given-names>G</given-names></name><name><surname>Sis</surname><given-names>B</given-names></name><name><surname>Reeve</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>2520</fpage>.<pub-id pub-id-type="pmid">19843030</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Terasaki</surname><given-names>PI</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Analysis of HLA class I specific antibodies in patients with failed allografts</article-title>.
<source><italic>Transplantation</italic></source>
<year>2007</year>;
<volume>83</volume>:
<fpage>54</fpage>.<pub-id pub-id-type="pmid">17220791</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mulay</surname><given-names>AV</given-names></name><name><surname>Cockfield</surname><given-names>S</given-names></name><name><surname>Stryker</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence</article-title>.
<source><italic>Transplantation</italic></source>
<year>2006</year>;
<volume>82</volume>:
<fpage>1153</fpage>.<pub-id pub-id-type="pmid">17102766</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group><name><surname>Ekberg</surname><given-names>H</given-names></name><name><surname>Bernasconi</surname><given-names>C</given-names></name><name><surname>Tedesco-Silva</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>1876</fpage>.<pub-id pub-id-type="pmid">19563339</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group><name><surname>Troppmann</surname><given-names>C</given-names></name><name><surname>Gruessner</surname><given-names>RW</given-names></name><name><surname>Matas</surname><given-names>AJ</given-names></name><etal></etal></person-group>
<article-title>Results with renal transplants performed after previous solitary pancreas transplants</article-title>.
<source><italic>Transplant Proc</italic></source>
<year>1994</year>;
<volume>26</volume>:
<fpage>448</fpage>.<pub-id pub-id-type="pmid">8171495</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mannon</surname><given-names>RB</given-names></name><name><surname>Matas</surname><given-names>AJ</given-names></name><name><surname>Grande</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2010</year>;
<volume>10</volume>:
<fpage>2066</fpage>.<pub-id pub-id-type="pmid">20883541</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group><name><surname>Matas</surname><given-names>AJ</given-names></name></person-group>
<article-title>Minimization of steroids in kidney transplantation</article-title>.
<source><italic>Transpl Int</italic></source>
<year>2009</year>;
<volume>22</volume>:
<fpage>38</fpage>.<pub-id pub-id-type="pmid">18662366</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group><name><surname>Woodle</surname><given-names>ES</given-names></name><name><surname>First</surname><given-names>MR</given-names></name><name><surname>Pirsch</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy</article-title>.
<source><italic>Ann Surg</italic></source>
<year>2008</year>;
<volume>248</volume>:
<fpage>564</fpage>.<pub-id pub-id-type="pmid">18936569</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group><name><surname>Knight</surname><given-names>SR</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name></person-group>
<article-title>Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis</article-title>.
<source><italic>Transplantation</italic></source>
<year>2010</year>;
<volume>89</volume>:
<fpage>1</fpage>.<pub-id pub-id-type="pmid">20061913</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group><name><surname>Matas</surname><given-names>AJ</given-names></name><name><surname>Granger</surname><given-names>D</given-names></name><name><surname>Kaufman</surname><given-names>DB</given-names></name><etal></etal></person-group>
<article-title>Steroid minimization for sirolimus-treated renal transplant recipients</article-title>.
<source><italic>Clin Transplant</italic></source>
<year>2011</year>;
<volume>25</volume>:
<fpage>457</fpage>.<pub-id pub-id-type="pmid">20497196</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal">
<person-group><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Muruganandham</surname><given-names>K</given-names></name><name><surname>Vinodh</surname><given-names>PB</given-names></name><etal></etal></person-group>
<article-title>Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors</article-title>.
<source><italic>Int Urol Nephrol</italic></source>
<year>2010</year>;
<volume>42</volume>:
<fpage>279</fpage>.<pub-id pub-id-type="pmid">19557542</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal">
<person-group><name><surname>Miles</surname><given-names>CD</given-names></name><name><surname>Skorupa</surname><given-names>JY</given-names></name><name><surname>Sandoz</surname><given-names>JP</given-names></name><etal></etal></person-group>
<article-title>Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus</article-title>.
<source><italic>Clin Transplant</italic></source>
<year>2011</year>;
<volume>25</volume>:
<fpage>898</fpage>.<pub-id pub-id-type="pmid">21077952</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group><name><surname>Pengel</surname><given-names>LH</given-names></name><name><surname>Liu</surname><given-names>LQ</given-names></name><name><surname>Morris</surname><given-names>PJ</given-names></name></person-group>
<article-title>Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials</article-title>.
<source><italic>Transpl Int</italic></source>
<year>2011</year>;
<volume>24</volume>:
<fpage>1216</fpage>.<pub-id pub-id-type="pmid">21955006</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal">
<person-group><name><surname>Nashan</surname><given-names>B</given-names></name><name><surname>Citterio</surname><given-names>F</given-names></name></person-group>
<article-title>Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature</article-title>.
<source><italic>Transplantation</italic></source>
<year>2012</year>;
<volume>94</volume>:
<fpage></fpage>.<pub-id pub-id-type="pmid">22941182</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">
<person-group><name><surname>Lebranchu</surname><given-names>Y</given-names></name><name><surname>Thierry</surname><given-names>A</given-names></name><name><surname>Toupance</surname><given-names>O</given-names></name><etal></etal></person-group>
<article-title>Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2009</year>;
<volume>9</volume>:
<fpage>1115</fpage>.<pub-id pub-id-type="pmid">19422337</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group><name><surname>Salgo</surname><given-names>R</given-names></name><name><surname>Gossmann</surname><given-names>J</given-names></name><name><surname>Schofer</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2010</year>;
<volume>10</volume>:
<fpage>1385</fpage>.<pub-id pub-id-type="pmid">20121752</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group><name><surname>Bunnapradist</surname><given-names>S</given-names></name><name><surname>Vincenti</surname><given-names>F</given-names></name></person-group>
<article-title>Transplantation: to convert or not to convert: lessons from the CONVERT trial</article-title>.
<source><italic>Nat Rev Nephrol</italic></source>
<year>2009</year>;
<volume>5</volume>:
<fpage>371</fpage>.<pub-id pub-id-type="pmid">19556993</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal">
<person-group><name><surname>Brennan</surname><given-names>DC</given-names></name><name><surname>Daller</surname><given-names>JA</given-names></name><name><surname>Lake</surname><given-names>KD</given-names></name><etal></etal></person-group>
<article-title>Rabbit antithymocyte globulin versus basiliximab in renal transplantation</article-title>.
<source><italic>N Engl J Med</italic></source>
<year>2006</year>;
<volume>355</volume>:
<fpage>1967</fpage>.<pub-id pub-id-type="pmid">17093248</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal">
<person-group><name><surname>Matas</surname><given-names>AJ</given-names></name><name><surname>Kandaswamy</surname><given-names>R</given-names></name><name><surname>Humar</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Long-term immunosuppression, without maintenance prednisone, after kidney transplantation</article-title>.
<source><italic>Ann Surg</italic></source>
<year>2004</year>;
<volume>240</volume>:
<fpage>510</fpage>.<pub-id pub-id-type="pmid">15319722</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kandaswamy</surname><given-names>R</given-names></name><name><surname>Melancon</surname><given-names>JK</given-names></name><name><surname>Dunn</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients—an interim analysis</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2005</year>;
<volume>5</volume>:
<fpage>1529</fpage>.<pub-id pub-id-type="pmid">15888064</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal">
<person-group><name><surname>Suszynski</surname><given-names>TM</given-names></name><name><surname>Gillingham</surname><given-names>KJ</given-names></name><name><surname>Rizzari</surname><given-names>MD</given-names></name><etal></etal></person-group>
<article-title>Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2013</year>;
<volume>13</volume>:
<fpage>961</fpage>.<pub-id pub-id-type="pmid">23432755</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal">
<person-group><name><surname>Preville</surname><given-names>X</given-names></name><name><surname>Flacher</surname><given-names>M</given-names></name><name><surname>LeMauff</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model</article-title>.
<source><italic>Transplantation</italic></source>
<year>2001</year>;
<volume>71</volume>:
<fpage>460</fpage>.<pub-id pub-id-type="pmid">11233911</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal">
<person-group><name><surname>Goggins</surname><given-names>WC</given-names></name><name><surname>Pascual</surname><given-names>MA</given-names></name><name><surname>Powelson</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients</article-title>.
<source><italic>Transplantation</italic></source>
<year>2003</year>;
<volume>76</volume>:
<fpage>798</fpage>.<pub-id pub-id-type="pmid">14501856</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kaden</surname><given-names>J</given-names></name><name><surname>May</surname><given-names>G</given-names></name><name><surname>Volp</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience</article-title>.
<source><italic>Ann Transplant</italic></source>
<year>2009</year>;
<volume>14</volume>:
<fpage>7</fpage>.<pub-id pub-id-type="pmid">19644154</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kyllonen</surname><given-names>LE</given-names></name><name><surname>Eklund</surname><given-names>BH</given-names></name><name><surname>Pesonen</surname><given-names>EJ</given-names></name><etal></etal></person-group>
<article-title>Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety</article-title>.
<source><italic>Transplantation</italic></source>
<year>2007</year>;
<volume>84</volume>:
<fpage>75</fpage>.<pub-id pub-id-type="pmid">17627241</pub-id></mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal">
<person-group><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath</article-title>.
<source><italic>J Am Coll Surg</italic></source>
<year>2005</year>;
<volume>200</volume>:
<fpage>505</fpage>.<pub-id pub-id-type="pmid">15804464</pub-id></mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal">
<person-group><name><surname>Starzl</surname><given-names>TE</given-names></name><name><surname>Murase</surname><given-names>N</given-names></name><name><surname>Abu-Elmagd</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Tolerogenic immunosuppression for organ transplantation</article-title>.
<source><italic>Lancet</italic></source>
<year>2003</year>;
<volume>361</volume>:
<fpage>1502</fpage>.<pub-id pub-id-type="pmid">12737859</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal">
<person-group><name><surname>Gore</surname><given-names>SM</given-names></name></person-group>
<article-title>Graft survival after renal transplantation: agenda for analysis</article-title>.
<source><italic>Kidney Int</italic></source>
<year>1983</year>;
<volume>24</volume>:
<fpage>516</fpage>.<pub-id pub-id-type="pmid">6358640</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="book">
<person-group><name><surname>Winer</surname><given-names>BJ</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Michels</surname><given-names>KM</given-names></name></person-group>
<source><italic>Statistical principles in experimental design</italic></source>. <edition>3rd ed</edition>
<publisher-loc>New York</publisher-loc>: 
<publisher-name>McGraw-Hill</publisher-name>; 
<year>1991</year>:
<fpage>xiii</fpage>.</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal">
<person-group><name><surname>Stevens</surname><given-names>RB</given-names></name><name><surname>Mercer</surname><given-names>DF</given-names></name><name><surname>Grant</surname><given-names>WJ</given-names></name><etal></etal></person-group>
<article-title>Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report</article-title>.
<source><italic>Transplantation</italic></source>
<year>2008</year>;
<volume>85</volume>:
<fpage>1391</fpage>.<pub-id pub-id-type="pmid">18497677</pub-id></mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal">
<person-group><name><surname>Metchnikoff</surname><given-names>E</given-names></name></person-group>
<article-title>Recherches sur l’influence de l’organisme sur les toxins: toxine tetanique et leukocytes</article-title>.
<source><italic>Ann Inst Pasteur</italic></source>
<year>1898</year>;
<volume>12</volume>:
<fpage>263</fpage>.</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal">
<person-group><name><surname>Woodruff</surname><given-names>M</given-names></name><name><surname>Forman</surname><given-names>B</given-names></name></person-group>
<article-title>Effect of antilymphocytic serum on suspensions of lymphocytes in vitro</article-title>.
<source><italic>Nature</italic></source>
<year>1951</year>;
<volume>168</volume>:
<fpage>35</fpage>.<pub-id pub-id-type="pmid">14852945</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal">
<person-group><name><surname>Monaco</surname><given-names>AP</given-names></name><name><surname>Abbott</surname><given-names>WM</given-names></name><name><surname>Othersen</surname><given-names>HB</given-names></name><etal></etal></person-group>
<article-title>Antiserum to lymphocytes: prolonged survival of canine renal allografts</article-title>.
<source><italic>Science</italic></source>
<year>1966</year>;
<volume>153</volume>:
<fpage>1264</fpage>.<pub-id pub-id-type="pmid">5331415</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal">
<person-group><name><surname>Najarian</surname><given-names>JS</given-names></name><name><surname>Simmons</surname><given-names>RL</given-names></name><name><surname>Gewurz</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man</article-title>.
<source><italic>Ann Surg</italic></source>
<year>1969</year>;
<volume>170</volume>:
<fpage>617</fpage>.<pub-id pub-id-type="pmid">4186508</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal">
<person-group><name><surname>Starzl</surname><given-names>TE</given-names></name><name><surname>Marchioro</surname><given-names>TL</given-names></name><name><surname>Porter</surname><given-names>KA</given-names></name><etal></etal></person-group>
<article-title>The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation</article-title>.
<source><italic>Surg Gynecol Obstet</italic></source>
<year>1967</year>;
<volume>124</volume>:
<fpage>301</fpage>.<pub-id pub-id-type="pmid">4163340</pub-id></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal">
<person-group><name><surname>Kaden</surname><given-names>J</given-names></name><name><surname>Strobelt</surname><given-names>V</given-names></name><name><surname>May</surname><given-names>G</given-names></name></person-group>
<article-title>Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation</article-title>.
<source><italic>Transplant Proc</italic></source>
<year>1998</year>;
<volume>30</volume>:
<fpage>4011</fpage>.<pub-id pub-id-type="pmid">9865279</pub-id></mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal">
<person-group><name><surname>Shapiro</surname><given-names>R</given-names></name><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath</article-title>.
<source><italic>J Am Coll Surg</italic></source>
<year>2005</year>;
<volume>200</volume>:
<fpage>505</fpage>.<pub-id pub-id-type="pmid">15804464</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal">
<person-group><name><surname>Stevens</surname><given-names>RB</given-names></name><name><surname>Lane</surname><given-names>JT</given-names></name><name><surname>Boerner</surname><given-names>BP</given-names></name><etal></etal></person-group>
<article-title>Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia</article-title>.
<source><italic>Clin Transplant</italic></source>
<year>2012</year>;
<volume>26</volume>:
<fpage>123</fpage>.<pub-id pub-id-type="pmid">21401720</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal">
<person-group><name><surname>Nankivell</surname><given-names>BJ</given-names></name><name><surname>Borrows</surname><given-names>RJ</given-names></name><name><surname>Fung</surname><given-names>CL</given-names></name><etal></etal></person-group>
<article-title>The natural history of chronic allograft nephropathy</article-title>.
<source><italic>N Engl J Med</italic></source>
<year>2003</year>;
<volume>349</volume>:
<fpage>2326</fpage>.<pub-id pub-id-type="pmid">14668458</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal">
<person-group><name><surname>Nankivell</surname><given-names>BJ</given-names></name><name><surname>Borrows</surname><given-names>RJ</given-names></name><name><surname>Fung</surname><given-names>CL</given-names></name><etal></etal></person-group>
<article-title>Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology</article-title>.
<source><italic>Transplantation</italic></source>
<year>2004</year>;
<volume>78</volume>:
<fpage>557</fpage>.<pub-id pub-id-type="pmid">15446315</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal">
<person-group><name><surname>Ducloux</surname><given-names>D</given-names></name><name><surname>Courivaud</surname><given-names>C</given-names></name><name><surname>Bamoulid</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation</article-title>.
<source><italic>J Am Soc Nephrol</italic></source>
<year>2010</year>;
<volume>21</volume>:
<fpage>868</fpage>.<pub-id pub-id-type="pmid">20203160</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal">
<person-group><name><surname>Schooley</surname><given-names>RT</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name><etal></etal></person-group>
<article-title>Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation</article-title>.
<source><italic>N Engl J Med</italic></source>
<year>1983</year>;
<volume>308</volume>:
<fpage>307</fpage>.<pub-id pub-id-type="pmid">6296673</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal">
<person-group><name><surname>Ducloux</surname><given-names>D</given-names></name><name><surname>Challier</surname><given-names>B</given-names></name><name><surname>Saas</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>CD4 cell lymphopenia and atherosclerosis in renal transplant recipients</article-title>.
<source><italic>J Am Soc Nephrol</italic></source>
<year>2003</year>;
<volume>14</volume>:
<fpage>767</fpage>.<pub-id pub-id-type="pmid">12595514</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal">
<person-group><name><surname>Tse</surname><given-names>K</given-names></name><name><surname>Tse</surname><given-names>H</given-names></name><name><surname>Sidney</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>T cells in atherosclerosis</article-title>.
<source><italic>Int Immunol</italic></source>
<year>2013</year>;
<volume>25</volume>:
<fpage>615</fpage>.<pub-id pub-id-type="pmid">24154816</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal">
<person-group><name><surname>Aukrust</surname><given-names>P</given-names></name><name><surname>Yndestad</surname><given-names>A</given-names></name><name><surname>Sandberg</surname><given-names>WJ</given-names></name><etal></etal></person-group>
<article-title>T cells in coronary artery disease: different effects of different T-cell subsets</article-title>.
<source><italic>J Am Coll Cardiol</italic></source>
<year>2007</year>;
<volume>50</volume>:
<fpage>1459</fpage>.<pub-id pub-id-type="pmid">17919565</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal">
<person-group><name><surname>Sureshkumar</surname><given-names>KK</given-names></name><name><surname>Thai</surname><given-names>NL</given-names></name><name><surname>Hussain</surname><given-names>SM</given-names></name><etal></etal></person-group>
<article-title>Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression</article-title>.
<source><italic>Transplantation</italic></source>
<year>2012</year>;
<volume>93</volume>:
<fpage>799</fpage>.<pub-id pub-id-type="pmid">22290269</pub-id></mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal">
<person-group><name><surname>Hanaway</surname><given-names>MJ</given-names></name><name><surname>Woodle</surname><given-names>ES</given-names></name><name><surname>Mulgaonkar</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Alemtuzumab induction in renal transplantation</article-title>.
<source><italic>N Engl J Med</italic></source>
<year>2011</year>;
<volume>364</volume>:
<fpage>1909</fpage>.<pub-id pub-id-type="pmid">21591943</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal">
<person-group><name><surname>LaCorcia</surname><given-names>G</given-names></name><name><surname>Swistak</surname><given-names>M</given-names></name><name><surname>Lawendowski</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion</article-title>.
<source><italic>Transplantation</italic></source>
<year>2009</year>;
<volume>87</volume>:
<fpage>966</fpage>.<pub-id pub-id-type="pmid">19352114</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mohty</surname><given-names>M</given-names></name></person-group>
<article-title>Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond</article-title>.
<source><italic>Leukemia</italic></source>
<year>2007</year>;
<volume>21</volume>:
<fpage>1387</fpage>.<pub-id pub-id-type="pmid">17410187</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mehrabi</surname><given-names>A</given-names></name><name><surname>Mood Zh</surname><given-names>A</given-names></name><name><surname>Sadeghi</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation</article-title>.
<source><italic>Nephrol Dial Transplant</italic></source>
<year>2007</year>;
<volume>22</volume>:
<fpage>viii54</fpage>.<pub-id pub-id-type="pmid">17890265</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal">
<person-group><name><surname>Bunnag</surname><given-names>S</given-names></name><name><surname>Einecke</surname><given-names>G</given-names></name><name><surname>Reeve</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Molecular correlates of renal function in kidney transplant biopsies</article-title>.
<source><italic>J Am Soc Nephrol</italic></source>
<year>2009</year>;
<volume>20</volume>:
<fpage>1149</fpage>.<pub-id pub-id-type="pmid">19389845</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mueller</surname><given-names>TF</given-names></name><name><surname>Reeve</surname><given-names>J</given-names></name><name><surname>Jhangri</surname><given-names>GS</given-names></name><etal></etal></person-group>
<article-title>The transcriptome of the implant biopsy identifies donor kidneys at increased risk of delayed graft function</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2008</year>;
<volume>8</volume>:
<fpage>78</fpage>.<pub-id pub-id-type="pmid">18021287</pub-id></mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mueller</surname><given-names>TF</given-names></name><name><surname>Einecke</surname><given-names>G</given-names></name><name><surname>Reeve</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2007</year>;
<volume>7</volume>:
<fpage>2712</fpage>.<pub-id pub-id-type="pmid">17941957</pub-id></mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal">
<person-group><name><surname>Gaber</surname><given-names>AO</given-names></name><name><surname>Monaco</surname><given-names>AP</given-names></name><name><surname>Russell</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology</article-title>.
<source><italic>Drugs</italic></source>
<year>2010</year>;
<volume>70</volume>:
<fpage>691</fpage>.<pub-id pub-id-type="pmid">20394456</pub-id></mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal">
<person-group><name><surname>Mueller</surname><given-names>TF</given-names></name></person-group>
<article-title>Mechanisms of action of thymoglobulin</article-title>.
<source><italic>Transplantation</italic></source>
<year>2007</year>;
<volume>84</volume>:
<fpage>S5</fpage>.</mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal">
<person-group><name><surname>Urbanova</surname><given-names>M</given-names></name><name><surname>Brabcova</surname><given-names>I</given-names></name><name><surname>Girmanova</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Differential regulation of the nuclear factor-kappaB pathway by rabbit antithymocyte globulins in kidney transplantation</article-title>.
<source><italic>Transplantation</italic></source>
<year>2012</year>;
<volume>93</volume>:
<fpage>589</fpage>.<pub-id pub-id-type="pmid">22334040</pub-id></mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal">
<person-group><name><surname>Sanz</surname><given-names>AB</given-names></name><name><surname>Sanchez-Nino</surname><given-names>MD</given-names></name><name><surname>Ramos</surname><given-names>AM</given-names></name><etal></etal></person-group>
<article-title>NF-kappaB in renal inflammation</article-title>.
<source><italic>J Am Soc Nephrol</italic></source>
<year>2010</year>;
<volume>21</volume>:
<fpage>1254</fpage>.<pub-id pub-id-type="pmid">20651166</pub-id></mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal">
<person-group><name><surname>Rangan</surname><given-names>GK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tay</surname><given-names>YC</given-names></name><etal></etal></person-group>
<article-title>Inhibition of nuclear factor-kappaB activation reduces cortical tubulointerstitial injury in proteinuric rats</article-title>.
<source><italic>Kidney Int</italic></source>
<year>1999</year>;
<volume>56</volume>:
<fpage>118</fpage>.<pub-id pub-id-type="pmid">10411685</pub-id></mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal">
<person-group><name><surname>Stevens</surname><given-names>RB</given-names></name><name><surname>Platt</surname><given-names>JL</given-names></name></person-group>
<article-title>The pathogenesis of hyperacute xenograft rejection</article-title>.
<source><italic>Am J Kidney Dis</italic></source>
<year>1992</year>;
<volume>20</volume>:
<fpage>414</fpage>.<pub-id pub-id-type="pmid">1415213</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal">
<person-group><name><surname>Stevens</surname><given-names>RB</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Kaji</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival</article-title>.
<source><italic>Transplant Proc</italic></source>
<year>1993</year>;
<volume>25</volume>
<issue>(1 Pt 1)</issue>:
<fpage>382</fpage>.<pub-id pub-id-type="pmid">8438344</pub-id></mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal">
<person-group><name><surname>Navarro</surname><given-names>FP</given-names></name><name><surname>Fares</surname><given-names>RP</given-names></name><name><surname>Sanchez</surname><given-names>PE</given-names></name><etal></etal></person-group>
<article-title>Brain heparanase expression is up-regulated during postnatal development and hypoxia-induced neovascularization in adult rats</article-title>.
<source><italic>J Neurochem</italic></source>
<year>2008</year>;
<volume>105</volume>:
<fpage>34</fpage>.<pub-id pub-id-type="pmid">17996027</pub-id></mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal">
<person-group><name><surname>Chappell</surname><given-names>D</given-names></name><name><surname>Jacob</surname><given-names>M</given-names></name><name><surname>Rehm</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Heparinase selectively sheds heparan sulphate from the endothelial glycocalyx</article-title>.
<source><italic>Biol Chem</italic></source>
<year>2008</year>;
<volume>389</volume>:
<fpage>79</fpage>.<pub-id pub-id-type="pmid">18095872</pub-id></mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal">
<person-group><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Clabaugh</surname><given-names>SE</given-names></name><name><surname>Smith</surname><given-names>DR</given-names></name><etal></etal></person-group>
<article-title>Interleukin-2 is present in human blood vessels and released in biologically active form by heparanase</article-title>.
<source><italic>Immunol Cell Biol</italic></source>
<year>2012</year>;
<volume>90</volume>:
<fpage>159</fpage>.<pub-id pub-id-type="pmid">21606942</pub-id></mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal">
<person-group><name><surname>Downie</surname><given-names>GH</given-names></name><name><surname>Ryan</surname><given-names>US</given-names></name><name><surname>Hayes</surname><given-names>BA</given-names></name><etal></etal></person-group>
<article-title>Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro</article-title>.
<source><italic>Am J Respir Cell Mol Biol</italic></source>
<year>1992</year>;
<volume>7</volume>:
<fpage>58</fpage>.<pub-id pub-id-type="pmid">1627337</pub-id></mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal">
<person-group><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gyorffy</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro</article-title>.
<source><italic>Inflammation</italic></source>
<year>1996</year>;
<volume>20</volume>:
<fpage>361</fpage>.<pub-id pub-id-type="pmid">8872500</pub-id></mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal">
<person-group><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Bosch</surname><given-names>JP</given-names></name><name><surname>Lewis</surname><given-names>JB</given-names></name><etal></etal></person-group>
<article-title>A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group</article-title>.
<source><italic>Ann Intern Med</italic></source>
<year>1999</year>;
<volume>130</volume>:
<fpage>461</fpage>.<pub-id pub-id-type="pmid">10075613</pub-id></mixed-citation></ref><ref id="R73"><label>73</label><mixed-citation publication-type="journal">
<person-group><name><surname>Solez</surname><given-names>K</given-names></name><name><surname>Colvin</surname><given-names>RB</given-names></name><name><surname>Racusen</surname><given-names>LC</given-names></name><etal></etal></person-group>
<article-title>Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’)</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2007</year>;
<volume>7</volume>:
<fpage>518</fpage>.<pub-id pub-id-type="pmid">17352710</pub-id></mixed-citation></ref><ref id="R74"><label>74</label><mixed-citation publication-type="journal">
<person-group><name><surname>Nyberg</surname><given-names>SL</given-names></name><name><surname>Matas</surname><given-names>AJ</given-names></name><name><surname>Kremers</surname><given-names>WK</given-names></name><etal></etal></person-group>
<article-title>Improved scoring system to assess adult donors for cadaver renal transplantation</article-title>.
<source><italic>Am J Transplant</italic></source>
<year>2003</year>;
<volume>3</volume>:
<fpage>715</fpage>.<pub-id pub-id-type="pmid">12780563</pub-id></mixed-citation></ref><ref id="R75"><label>75</label><mixed-citation publication-type="book">
<person-group><name><surname>Verbeke</surname><given-names>G</given-names></name><name><surname>Molenberghs</surname><given-names>G</given-names></name></person-group>
<source><italic>Linear Mixed Models for Longitudinal Data</italic></source>. 
<publisher-name>Springer Verlag</publisher-name>; 
<year>2009</year>.</mixed-citation></ref></ref-list></back></article>